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ABSTRACT

Effect of n-3 and n-6 Polyunsaturated Fatty Acids on Inflammation
by
Tao Xu, Doctor of Philosophy
Utah State University, 2017

Major Professor: Dr. Robert E. Ward
Department: Nutrition, Dietetics, and Food Sciences
Intake of polyunsaturated fatty acids (PUFA) has changed drastically in the past
century in the American diet and has received attention due to potential effects on chronic
inflammation-related metabolic diseases. In this project, the effects of dietary PUFA
content and the n-6 to n-3 ratio on inflammatory responses in the acute and chronic
inflammation models were evaluated. The PUFA content was modified on a Western diet
background to deliver both n-6 and n-3 intakes at the 10th and 90th percentile of the
population in the United States, and models of acute and chronic inflammation were
tested in mice model. The experimental PUFA diets had a modest effect on the response
to lipopolysaccharide (LPS) in the acute inflammation model. A high n-6 to n-3 ratio
promoted lipogenesis. In addition, high n-6 PUFA enhanced the inflammatory responses
via the NF-κB pathway. In chronic inflammation model, low-grade inflammatory stress
was induced by osmotic mini-pump delivery of LPS. A high n-6 intake increased glucose
intolerance. On the other hand, high n-6 intake promotes cholesterol ester accumulation
in both acute and chronic inflammation models.
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PUBLIC ABSTRACT

Effect of n-3 and n-6 Polyunsaturated Fatty Acids on Inflammation
Tao Xu

The purpose of this study is to evaluate the effects of dietary PUFA on
inflammatory responses. Dietary PUFAs have shown to have the effects on various
chronic diseases caused by inflammation. In our study, acute inflammation and chronic
inflammation were developed on the mice model to test the hypotheses. The PUFA diets
modified from a Western diet background to deliver both n-6 and n-3 intakes at the 10th
and 90th percentile of the population in the United States were used in the study. The
experimental PUFA diets had a modest effect on the response to LPS in the acute
inflammation model. A high n-6 to n-3 ratio promoted lipogenesis. In addition, high n-6
PUFA enhanced the inflammatory responses via the NF-κB pathway. In chronic
inflammation model, low-grade inflammatory stress was induced by osmotic mini-pump
delivery of LPS. The PUFA diets also had a modest effect on inflammation responses in
the chronic model. A high n-6 intake increased glucose intolerance. The study indicated
that dietary PUFA content and ratio under physiological range of intake would only cause
modest effect on inflammation in vivo which gives useful information for dietary
guidelines for Americans. The overall cost of this research was approximately 20,000
dollars.
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CHAPTER 1

INTRODUCTION

Dietary fats
The typical American diet is composed of approximately 50% carbohydrate, 15%
protein, and 35% fat (1). Compared with carbohydrates and proteins, each gram of fat
provides more than double the calories (carbohydrates 4.183 kcal/g; protein 4.442 kcal/g;
fat 9.461 kcal/g) (2). Another difference between fat and the other macronutrients, from a
nutrition perspective, is that the lipid composition of an organism’s membranes reflect
the dietary lipid intake (3). In terms of dietary fat, you literally are what you eat.
Therefore, compared to protein and carbohydrate, dietary fats may have a greater
potential to impact physiological processes.
Many studies have been done to investigate the relationship between dietary fat
composition and disease. There is substantial evidence that dietary fat is associated with
cardiovascular diseases (CVD) risk (4-6). There is general consensus that reduction of
dietary saturated fatty acids (SFA) could reduce the risk of coronary heart disease (CHD)
by decreasing serum total cholesterol and low-density lipoprotein (LDL) cholesterol (79). Beyond CVD, dietary fat can impact other metabolic diseases such as non-alcoholic
fatty liver disease (NAFLD), type 2 diabetes, and Alzheimer’s disease (10-13).
Fatty acids
Fatty acids consist of a carboxylic acid (head) and an aliphatic tail. In humans,
saturated fatty acids are synthesized up to 16-carbon (palmitic acid) by fatty acid
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synthases (FAS) in the cytoplasm. The pathway for fatty acids synthesis begins with
malonyl CoA and acetyl CoA which are activated by thioester bonds to FAS. Then, twocarbon units (donated by activated malonate) are added onto the chain through every
cycle. CO2 is eliminated from the added malonyl CoA in each cycle which results in fatty
acids with even carbon chains (14).
Although humans can synthesize fatty acids, other fatty acids that cannot be
synthesized de novo are required. This is due to lack of Δ12 and Δ15 desaturases, which
introduce double bonds at carbons 12 and 15 (when counting from the carbonyl carbon)
(15, 16). Consequently, it is necessary to acquire certain fatty acids from the diet. Those
fatty acids are called essential fatty acids (17). There are two fatty acids that are essential
for humans, linoleic acid (LA) and α-linolenic acid (ALA) (18). LA and ALA are both
polyunsaturated fatty acids (PUFA) with 18-carbon aliphatic chains. The differences
between LA and ALA are: 1) LA has two cis double bonds while ALA has three cis
double bonds; 2) the first double bond of LA located at the 6th carbon from the methyl
end which we call omega-6 (nomenclature systems will be discussed shortly) while ALA
has the first double bond located at the 3rd carbon from the methyl end and is referred to
as an omega-3 fatty acid (19). Using LA and ALA as substrates, longer and more highly
unsaturated fatty acids can be produced by elongases and desaturases in the mitochondria
and microsomes (20).
Based on the number of double bonds in the aliphatic chain, fatty acids are
classified to three different groups which are saturated fatty acids (SFA) (no double
bond), monounsaturated fatty acids (MUFA) (one double bond), and PUFA (more than
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one double bonds) (21). For PUFA, there are two common nomenclature systems, the
delta system and the omega system (or ―n-minus‖ system). The delta system counts the
position of double bonds from the carboxyl end (alpha carbon) to the first unsaturated
carbon. For example, ALA is named as 18:3 Δ9,12,15. The omega system, conversely,
counts from the terminal methyl carbon (omega carbon) to the first unsaturated carbon.
Thus, ALA is named as 18:3 (ω-3) (22). Often, ―n‖ is used in place of the ―ω‖. The delta
system is the standard chemistry nomenclature (IUPAC system) which is the most
comprehensive for naming fatty acids, and is useful for those in the molecular chemistry
since the name of all the fatty acids are unambiguous (23). However, from a nutrition
stand point, the omega system is more commonly used because of the important
physiological differences between omega-3 (n-3) and omega-6 (n-6) fatty acids (24). The
reason that the omega system is more useful from a nutrition perspective is that all longer
and more highly unsaturated n-3 PUFAs are synthesized from ALA and all n-6 PUFAs
are from LA.
Dietary SFAs, MUFAs, and PUFAs have different effects on human health. For
example, in vivo inflammatory responses, SFAs are generally considered to promote
inflammatory process (25-28) while MUFAs are thought to have neutral or opposite
effects on inflammation. On the other hand, PUFAs have more complicated interactions
with the inflammatory responses which are discussed below.
PUFA
Dietary fatty acids, especially PUFAs, are widely studied not only for their
relationships to different diseases but also for their essentiality in human diet. In the last
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century, Americans’ diets have changed drastically in terms of PUFA intake.
Consumption of LA has increased from 2.79% of energy to 7.21% of energy while intake
of ALA has increased from 0.39% to 0.72% (29). Data from National Health and
Nutrition Examination Survey (NHANES) indicates that the range of n-6 PUFA intake of
Americans is from 5.1% of total energy (10th percentile population) to 10.4% of total
energy (90th percentile population) while n-3 PUFA intake is from 0.4% (10th percentile
population) to 1.1% (90th percentile population) (1). Thus, dietary n-6 PUFA intakes from
5.1% to 10.4% and dietary n-3 PUFA intakes from 0.4% to 1.1% would include 80% of
the population in the United States. In other words, if different PUFA intakes are
affecting health in the US diet, the intake of n-3 and n-6 PUFA should be within these
ranges.
Although PUFA intake is affected by many factors, one important reason that
PUFA consumption has increased is due to the use of vegetable oils in cooking and in
processed foods. It has been recommended to Americans to consume more PUFAs by the
U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human
Services (HHS) due to their cardiovascular benefits (30). In general, research with dietary
PUFA has shown positive effects on CVD by lowering both total serum cholesterol and
LDL cholesterol (7, 31, 32) and reducing blood pressure (33, 34).
Beyond the lowering of serum cholesterol, might the dramatic change in PUFA
intake in the last century have other health effects? The overall effects on health of
dietary PUFA arise from both their metabolic properties and role in cellular signaling
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processes. The process of essential fatty acid elongation and desaturation is shown in
Figure 1.1.

FIGURE 1.1

Biosynthesis of PUFAs from EFA

From the Figure 1.1, it can be noted that all n-6 PUFAs such as AA are derived
from LA while the n-3 PUFAs such as eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) are derived from ALA. These pathways also explain the value of the omega
nomenclature system, as the position of the n-6 and n-3 double bonds does not change as
the molecules are elongated and further desaturated. Since the typical American diet
contains an excess of LA (n-6) over ALA (n-3), the in vivo concentration of Arachidonic
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acid (AA) (n-6) is significantly higher than EPA (n-3) in tissue long chain PUFA which
may contribute to inflammatory processes and chronic diseases (35).
Intakes of PUFA have changed in the last century as have rates of obesity and
related metabolic diseases like diabetes (36, 37). Interestingly, these metabolic diseases
are associated with a low-grade, chronic inflammation (38, 39). On the other hand,
research has suggested another aspect of dietary PUFA may impact cardiovascular health:
the n-6 to n-3 PUFA ratio should also be considered in the US dietary guidance (40, 41).
Does n-6 to n-3 PUFA ratio in the diet affect the inflammatory responses in humans? To
better understand these two questions, it is critical to understand the mechanism of
inflammatory pathway of n-3 and n-6 PUFAs.
Inflammation and related cytokines, gene expression
Inflammation is a complex host response to eliminate the foreign invaders, such
as infectious pathogens, as well as damaged tissues (42). It is a biological mechanism
used to kill pathogens, initiate tissue repair, and restore homeostasis at an infection or
injury site. The inflammatory process can be regulated through activation of negative
feedback mechanisms such as releasing anti-inflammatory signals (cytokines), or
inhibiting the generation of pro-inflammatory signaling cascades (43). On the other hand,
if not controlled, excessive inflammation can cause damage to host tissues and also lead
to a series of human diseases (44).
Depending on the specific process, inflammation could be categorized as acute or
chronic. Acute inflammation normally occurs over short time (hours to days) whereas
chronic inflammation is continuous over longer time frames. Microbial (bacterial, viral,
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fungal, and parasitic) toxins are common stimuli for the initiation of acute inflammation
(42). The immediate responses of acute inflammation are usually triggered by various
inflammatory mediators in the tissues which recruit immune cells such as neutrophils and
polymorphonuclear leukocytes (45). On the other hand, chronic inflammation is
commonly caused by low grade endotoxemia such as lipopolysaccharide (LPS) (46),
cellular stress and malfunction. In chronic inflammation, monocytes and long-lived
macrophages are mainly involved in the immune responses (47). High-fat diets have also
been shown to cause metabolic endotoxemia in animals and humans. High-fat diets can
enhance translocation of LPS from the gut to the systemic circulation which eventually
induces systemic chronic inflammation (48, 49).
Stimuli for the initiation of inflammation include microbial cell wall components
such as LPS. LPS consists a lipid and a polysaccharide bound by a covalent bond. It is a
component of the outer membrane of Gram-negative bacteria. The immune system
recognizes LPS via Toll-like receptors (TLR). While gut-derived endotoxin is thought to
be one factor that promotes metabolic endotoxemia, there are endogenous protection
mechanisms in place to handle this potential stress. For example, intestinal alkaline
phosphatase (IAP) is a protective enzyme that detoxifies LPS by removal of a phosphate
group, which prevents gut-derived systemic inflammation (50). Interestingly, it was also
reported that L-phenylalanine (L-Phe) inhibits endogenous IAP activity which increases
serum endotoxin levels and promotes metabolic inflammation (51). L-Phe supplement in
the diet could be a suitable model to cause chronic inflammation.
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One of the key links between inflammation and PUFAs are eicosanoids, which
are oxidized compounds generated from 20-carbon PUFAs (44). AA (20:4 n-6) is the
major substrate for biosynthesis of eicosanoids (52). Figure 1.2 shows several pathways
of eicosanoids syntheses which are generated from AA. In vivo, AA concentration can be
affected by dietary intake of AA itself (53) or of its precursor, LA. However, the range of
LA intakes which affects this relationship has not been defined. More importantly, AA in
the cell membranes can be partially replaced by EPA which would be predicted to
decreases production of AA-derived eicosanoids (54).

FIGURE 1.2

Effect of PUFA substrate on eicosanoid biosynthesis (55, 56)
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As shown in the Figure 1.2, AA can be converted to eicosanoids resulting in
different groups of compounds such as thromboxanes, leukotrienes, prostaglandins, and
other oxidized PUFA metabolites. Prostaglandin-D2 (PGD2) promotes the neutrophil
recruitment process. However, EPA is an alternate substrate for cyclooxygenase (COX)
which leads to the production of PGD3 which competes for the PGD2 receptor to inhibit
the migration of neutrophils across endothelial cells (57-59). Another AA-derived
eicosanoid, PGE2 has been demonstrated to induce production of Interleukin-6 (IL-6)
which is a pro-inflammatory cytokine produced by macrophages (60). However, other
studies have indicated PGE2 promotes anti-inflammatory effects through 15-lipoxygenase
(15-LOX) induction to promote lipoxin generation (61, 62). Another eicosanoid,
leukotriene B4 (LTB4), is a powerful inducer of leukocyte chemotaxis and adherence
which leads to pro-inflammation (63).
In the inflammatory process, 20-carbon n-3 PUFAs may serve as substrates for
the biosynthesis of eicosanoids to prevent conversion of AA to pro-inflammatory
eicosanoids. Numerous studies have shown that PUFA-derived mediators, such as
resolvins, docosatrienes, and neuroprotectins, generated from EPA and DHA have antiinflammatory function (64-66). Similar to PGD3, long chain n-3 PUFAs are able to
modulate prostaglandin metabolism by increasing PGE3 (an active vasodilator and
inhibitor of platelet aggregation) and LTB5 (weak inducer of inflammation) (67).
Various cytokines and associated genes are involved in the PUFA-related
inflammatory processes and are useful as biomarkers to measure inflammation.
Cytokines are low-molecular-weight proteins produced by immune cells such as
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macrophages, neutrophils, T- and B-lymphocytes which regulate the immune system (68).
Metabolic disorders may trigger a persistent inflammatory cascade including production
of eicosanoids (lipid autacoids) which recruit immune cells to the site of inflammation to
secrete cytokines (69). Thus, measurement of cytokines could also be a useful endpoint
of evaluating downstream inflammatory responses.
Studies have demonstrated that lipid components of the diet can modulate
transmembrane TLRs which may consequently affect the vigor of immune responses (70).
EPA and DHA have been shown to act as inhibitors of various TLRs and nod-like
receptors (NLRs) and suppress nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) related signal transduction (27, 28, 71-73). NF-κB has dual intracellular
effects on inflammation. It induces proteins promoting survival in the acute cellular stress
responses (74). It is also a pro-inflammatory transcription factor which upregulates the
expression of pro-inflammatory cytokines and adhesion molecules (75). In LPS-induced
inflammation, LPS interacts with a heterologous receptor which contains TLR4, cluster
of differentiation-14 (CD14), and lymphocyte antigen 96 (MD2) to activate the complex
(76). Then, the adapter protein MYD88 is recruited to the cytoplasmic domain of TLR4
complex through homotypic binding of Toll/interleukin-1 receptor (TIR) domains (77,
78). Subsequently, recruitment of Interleukin-1 receptor-associated kinase (IRAK) and
TNF (Tumor necrosis factor alpha) receptor-associated factor-6 (TRAF6) on the complex
can result in the activation of a downstream kinase cascade involving inhibitor of
inhibitor of nuclear factor kappa B kinase (IKK). The IKK-mediated phosphorylation of
inhibitor of nuclear factor kappa B (IκB) leads to degradation of IκB by proteasome and
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allows NF-κB translocate to the nucleus from cytosol which promotes the proinflammatory gene expression (see Fig. 1.3) (79). Eventually, the immune response
involves the expression of pro-inflammatory cytokines like tumor necrosis factor α (TNFα), IL-1α, IL-1β, IL-6, monocyte chemotactic protein 1 (MCP-1), and macrophage
inflammatory protein 1α (MIP-1α) will be initiated (80-83). Liuzzo et al. also found that
C-reactive protein (CRP) had pro-inflammatory effect via NF-κB pathway which can be
another interesting endpoint to measure (84).
Eicosanoids have been extensively linked to the NF-κB pathway which might
have a close relationship to LPS-induced inflammation. Erdinest et al. indicated that
resolvin D1 (generated from DHA) had inhibitory effects on Poly I:C induction which
caused decreased IκB-α expression in the human corneal epithelial cells (85). Resolvin
E1 also showed anti-inflammatory effect through inducing IAP expression and enhancing
epithelial IAP enzyme activity (86). IAP detoxifies LPS which attenuates LPS-induced
NF-κB pathway and eventually represses NF-κB involved inflammation (87). On the
other hand, AA-derived eicosanoids are more likely to promote the inflammation via
activation of NF-κB pathway. Hydroxyeicosatetraenoic acids (HETEs), one of the major
eicosanoids generated from AA, have been reported to promote the NF-κB pathway. For
example, Ishizuka et al. demonstrated that 20-HETE activates the NF-κB pathway and
increases nuclear translocation of NF-κB p65 subunit in human endothelial cells (88). 15HETE promotes the IκB-α phosphorylation and degradation to activate the NF-κB
transcription pathway (89). Eicosanoids generated from PUFAs mainly affect LPSinduced NF-κB pathway (Fig. 1.3) via IκB-α activation or deactivation (90).
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FIGURE 1.3

LPS induced NF-κB pathway (91)

Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors
which belong to nuclear receptors superfamily. Subtypes of PPARs include PPAR-α,
PPAR-β, and PPAR-γ. PUFAs and eicosanoids are natural ligands for PPARs (92, 93). In
rodents and humans, PPAR-α is expressed in tissues such as liver, skeletal muscle, and
brown fat which is associated with fatty acid oxidation. In general, n-3 PUFAs act as
activators of PPAR-α (94). PPAR-α agonists exert anti-inflammatory effects in vascular
cells which involves inhibition of cytokine-induced expression of adhesion molecules
(95). PPAR-α agonists reduce IL-6 concentration in the plasma and decrease the
expression of COX-2 by repressing NF-κB signaling. PPAR-α physically interacts with
NF-κB p65 subunit to form inactive complexes which interfere its transcription activity
(96). Also, PPAR-α activators inhibit NF-κB-driven gene transcriptions by inducing IκBα gene expression and its protein translocation which accelerates NF-κB nuclear
deactivation (97). Other studies showed PPAR-α activation by n-3 PUFA was evidenced
by enhancement in the PPAR-α-regulated Acox and Cpt-1 gene expression which are
critical enzymes for β-oxidation of lipids (75). PPAR-β is expressed in myeloid cells.
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Activation of PPAR-β will cause the repression of inflammatory genes such as Ccl2 gene
(C-C motif chemokine ligand 2, MCP-1) (92). PPAR-γ is expressed in white and brown
adipose tissue, colon, endothelial cells, vascular smooth muscle cells (VSMCs), and
macrophages. Activation of PPAR-γ results in strong suppression of various proinflammatory cytokines including TNF-α and IL-6 in cultured macrophages (98). One
study showed that the n-3 PUFA-derived eicosanoid 15d-PGJ3 can enhance the
expression of PPAR-γ targeted genes such as fatty acid binding protein-4 gene (Fabp4)
(99). Interestingly, n-6 PUFA-derived 15d-PGJ2 (the dehydration end product of PGD2)
and 8(S)-HETE are potential agonists of PPAR-α and PPAR-γ and inhibits activation of
NF-κB (100-102). In the LPS-induced inflammation, PPARs are also shown to inhibit
LPS-induced high-mobility group protein B1 gene (Hmgb1) (103). In fact, the interaction
of Hmgb1 and TLR4 leads to upregulation of NF-κB (104).
On the other hand, PUFAs may also affect inflammatory mediators via
suppressing lipogenesis genes. For example, n-3 PUFAs repress sterol regulatory element
binding protein-1 gene (Srebp-1) (105). SREBP1 promotes diacylglycerol Oacyltransferase-2 (DGAT2) which catalyzes diacylglycerol and acyl-CoA to form
triglycerides, Acetyl-CoA carboxylase-1 (ACACA) which catalyzes carboxylation of
acetyl-CoA to malonyl-CoA, and fatty acid synthases (FAS) activities (106). Also,
studies have shown decreased activity of malic enzyme-1 (ME1) (generating NADPH for
fatty acid biosynthesis) in rats fed with high n-3 PUFA diets (107). Elongation of very
long chain fatty acids acyl elongase-5 (ELOVL5), an enzyme which is critical in C20-22
PUFA synthesis, may be enhanced in animals fed a high PUFA diet (C18 PUFAs) (108).
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More than that, LA and ALA inhibit stearoyl-CoA desaturase-1 (SCD-1), the enzyme
which adds a double bond to stearoyl-CoA and produces oleic acid (109). With high
dietary n-3 PUFA level, reduced level of FAS in the rat liver was measured (107, 110).
In short, activation of NF-κB pathway from LPS triggers the inflammatory
responses. N-3 PUFAs and their eicosanoids are able to attenuate the NF-κB pathway
which results anti-inflammatory activity in cells while n-6 PUFAs and their eicosanoids
promote this pathway. PPAR-α pathway promotes β-oxidation which is the opposite of
lipogenesis. PPARs also show inhibitory effects on NF-κB pathway. Evidence indicates
that eicosanoids generated from n-3 PUFAs are associated to enhancement of PPARs
pathway while n-6 PUFAs inhibit the process. In lipogensis, high level of PUFAs,
especially n-3 PUFAs, are thought to inhibit the fatty acid synthesis. Thus, measuring
NF-κB signaling, PPARs pathway and lipogenesis related genes will be critical for us to
understand the effects of PUFA contents and ratios on LPS-induced inflammation. In
summary, these three pathways associated genes are listed in the Table 1.1.

TABLE 1.1

Inflammatory pathways related genes.

NF- κB pathway
IκB-α
IL-1α
IL-1β
IL-6
TNF-α
Ccl2 (MCP-1)
Ccl3 (MIP-1α)
CRP
NF-κB1
Hmgb1

PPARs pathway
Hmgb1
Acox1
Cpt-1
Ppar

Lipogensis
Srebp-1
Scd-1
Acaca
Fasn
ME-1
Dgat2
Elovl5
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Effects of modifying dietary PUFAs in rodent diets and preliminary studies
Before investigating the relationship between dietary PUFA intake and
inflammation, it is necessary to define the model. First, what would be a suitable diet to
study the relationship between inflammation and dietary PUFA intake? Secondly, does
dietary PUFA %kcal, PUFA ratio, or both affect the inflammatory responses?
Many groups have used mouse models to investigate the effects of dietary n-6 to
n-3 PUFA on inflammation. Lots of studies indicate high n-6 to n-3 PUFA ratio enhance
the inflammatory responses in both animal and human models (111-117). On the contrary,
other studies have shown that a high dietary n-6 to n-3 PUFA ratio does not show a
significant increase on inflammatory biomarkers (118, 119).
In previous work in our lab, the effects of both the PUFA content and n-6 to n-3
ratio were investigated (120). AIN93-based PUFA diets with total PUFA percentage at
2.5%, 5%, 10% of kcal and n-6 to n-3 PUFA ratios at 1:1, 10:1, 20:1 were used. After 8
weeks feeding, a sub lethal dose of LPS was injected into mice to cause acute
inflammation. The preliminary results indicated that the PUFA content had an effect on
feed efficiency (weight gain to food intake ratio) with low dietary n-6 to n-3 PUFA ratio
leading to more fat gain in mice. Furthermore, in the cytokine analysis, mice fed with
lower PUFA percentages had lower concentration of interferon-γ (INF-γ), IL-5, IL-6, IL10, IL12, IL-1β, IL-17, IL-3, and chemokine ligand 5 (RANTES). Four cytokines
including IL-3, TNF-α, RANTES, and MCP-1 indicated differences between diets with
different PUFA ratios. Six cytokines including IL-17, IL-3, MIP-1α, TNF-α, RANTES,
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and MCP-1 showed differences because of the interaction of total PUFA percentages and
PUFA ratios. The summary of cytokines is shown in the Figure 1.4.

FIGURE 1.4 Log(10) transformed cytokine levels in the mice plasma. The ratios in the
legend represent n-6 to n-3 PUFA ratios in the diets. The data represents mean ± SD.

As can be seen in Figure 1.4, TNF-α, MCP-1, and MIP-1α showed significantly
lower levels in the 1:1 n-6 to n-3 PUFA ratio under diet with 10% energy from PUFAs,
while IL-6, INF-γ, and IL-1β were only affected by total PUFA content (120).
Interestingly, MCP-1 and MIP-1α both belong to C-C chemokines which induce the
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recruitment and migration of leukocytes into inflammatory area (121). This suggests that
dietary PUFA contents and ratios may affect different inflammatory pathways. However,
we need to note that n-6 to n-3 PUFA ratio at 1:1 used in our previous study was very
extreme. In our current study, we used physiologically relevant PUFA intakes, based on
NHANES, which should indicate whether differential intakes are likely to affect health.
In another study conducted in the Ward Lab (unpublished), the effects of dietary
PUFA percent and n-6 to n-3 ratios were tested on chronic inflammation. Many studies
have shown diet induced obesity (DIO) diets, or high fat diets with a kcal from fat
percentage >45%, cause obesity and chronic inflammation in mice (122-126). Thus, DIO
diets with different PUFA levels (5% & 10% for n-6 PUFA and 1% & 5% for n-3 PUFA)
and n-6 to n-3 PUFA ratios (1:1, 2:1, 5:1, and 10:1) were formulated to be tested in a 2 ×
2 design. Mice were fed for 18 weeks, which has been shown to be sufficient to cause an
obese and inflamed phenotype in most studies. Surprisingly, the results indicated no
significant differences in weight gain, inflammation or any metabolic parameters
measured among different PUFA diets. Although the mice fed the DIO diets had
significantly more body fat than mice fed the AIN93 diet, there were no differences in
insulin sensitivity, plasma cytokines or inflammatory gene expression in adipose or liver.
This is not the only time high PUFA DIO diets have not shown a difference on
inflammation biomarkers. Murphy et al. used a similar design by using high fat diet with
n-6 to n-3 PUFA ratios at 1:1, 5:1, 10:1, and 20:1. They also concluded that reduced
dietary n-6 to n-3 PUFA ratio by using ALA did not affect inflammation (119). The
previous studies from other labs and our lab do not have a consistent conclusion for the
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relationship between dietary PUFA intake and inflammation. However, we need to pay
attention to relatively high risk of false negative results (Type II error) due to the small
sample size in our previous experiment (127).
There are some methodological issues with previous studies that may explain
differing results. First, the basic diet composition used in studies likely has an effect with
respect to the PUFA contents. Many studies used standardized mouse diets such as the
AIN76 and AIN93 diets which do not represent the typical Western diets eaten by
Americans. AIN diets were optimized for rodent growth and fertility (128, 129).
However, the daily meals American people eat have less than recommended amounts of
micronutrients and much higher fat content. Using standardized mice diet to study effects
of dietary PUFA intakes of Americans on human health may thus hide important effects.
To address this issue, Drs. Ward, Hintze, and Benninghoff developed a new rodent diet
formula to emulate the typical Western diet based on median American intakes of
macronutrients and micronutrients (1, 130). The median intakes of American diets were
investigated by NHANES for the years 2005-2006 (130). In the survey, total energy
intake, sources and intakes of macronutrients, and most of the essential micronutrients
were investigated. To match the median dietary macronutrients and micronutrients levels
of Americans, TWD was designed and formulated using the concept of nutrient density
(mass of nutrient per kcal). Compared to standard diets for mice like AIN76 and AIN93
diets which have much lower fats and optimized concentration of micronutrients, TWD is
a more physiologically relevant diet as it represents what Americans are actually eating.
The second concern is the PUFA compositions in the diets. In previous studies, the PUFA
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sources, contents and ratios used have been extreme compared to that which is typically
consumed on average. Our PUFA diets were designed based on TWD with different n-6
PUFA and n-3 PUFA contents. The levels of n-6 and n-3 PUFAs were formulated based
on the intakes of 10th percentile population (low limit) and intakes of 90th percentile
population (high limit) from NHANES. Thus, our PUFA diets can represent the realistic
dietary PUFA intakes extremes that Americans are actually consuming.
Based on the design of our PUFA diets, if dietary PUFA do have effects on
human inflammatory responses, differences of inflammatory biomarkers we selected
would be observed among our PUFA diets with different n-6 and n-3 PUFA contents and
different n-6 to n-3 PUFA ratios. If there is no significant effect, then it would lead us to
another conclusion that the PUFA intakes of Americans are not likely to affect the
inflammation.
Summary
In summary, to achieve our goals of this thesis, the models of in vivo acute and
chronic inflammation were established, and the effects of dietary PUFA contents and
ratios on both acute inflammation and chronic inflammation models were investigated.
TWD-based PUFA diets with different n-6 and n-3 PUFA contents and different n-6 to n3 PUFA ratios were designed and used in our inflammation models. The effects of LPS
on NF-κB and PPARs signaling as well as on and were studies as a function of dietary
PUFA content. Endpoints assessed included weight gain, fat gain, fatty acid profile, oral
glucose tolerance test (OGTT), cytokines, and gene expression levels.
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CHAPTER 2

EFFECT OF DIETARY N-6 AND N-3 PUFA IN AN ACUTE INFLAMMATION

MODEL

Introduction
Over the past 100 years, dietary PUFA intake in the US has changed significantly
due to increased use of vegetable oils in cooking and processed foods. The consumption
of LA has increased from 2.79% of energy to 7.21% of energy while intake of ALA has
increased from 0.39% to 0.72% (1). Might these changes have an effect on physiology
and health?
In general, n-6 PUFAs are considered to have pro-inflammatory properties while
n-3 PUFAs are considered anti-inflammatory (2). The lipid composition of an organism’s
membranes roughly reflects dietary fat intake due to the functional requirements of lipids
in the membranes (3). In addition, tissue PUFA levels may mediate the inflammatory
responses through their metabolic products, eicosanoids. Thus, studying the effects of
dietary PUFA intake on inflammation provides important information for understanding
the role of fat in a healthy diet.
As there is both acute and chronic inflammation, it is of interest to determine how
dietary PUFA may affect both responses. In previous work, Drs. Ward and Hintze
investigated how both the percent PUFA intake and n-6 to n-3 ratio affected the cytokine
response in an acute inflammatory stress in LPS-challenged mice (4). Mice were fed diets
that contained either 2.5%, 5% or 10% kcal from PUFA, at n-6 to n-3 ratios of 1:1, 10:1
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and 20:1 and then injected intraperitoneally with a sub lethal dose of LPS (5 mg/kg).
Interestingly, the %PUFA in the diet significantly affected 11 of 12 cytokines measured,
whereas the n-6 to n-3 ratio affected only 5 of 12. For 7 of 12 cytokines there was a
PUFA × ratio interaction. While the results of this study indicated that dietary PUFA can
affect the acute inflammatory response, there were methodological details that may limit
its translatability to human PUFA intakes. First, the PUFAs intakes were not within
average US ranges of human intake. Next, the background diet used in the study
(AIN93G) is a low fat diet (17% kcal) and which was formulated to deliver optimum
levels of vitamins and minerals.
Other groups have investigated the role of dietary PUFA in inflammatory
processes in mice. For example, Broughton et al. found a low n-6 to n-3 diet ratio
increased anti-inflammatory eicosanoid biosynthesis compared a high ratio (5). However,
the diets were extreme in the ratios and paired short chain n-6 with long chain n-3 fatty
acids. The diets used had, at one extreme, an n-6:n-3 ratio of close to infinity (i.e. almost
no omega-3) and at the other extreme a 1:1 ratio, which contained far more long-chain n3 than most Americans eat. According to NHANES for the years 2005-2006, the average
n-6 PUFA intake was 7.1% of total energy and n-3 PUFA intake was 0.7% of total
energy. Thus, the PUFA intake is ~8% kcal, with an average n-6:n-3 ratio of 10:1.
With diet limitations in mind, Drs. Ward, Hintze, and Benninghoff developed the
Total Western Diet (TWD) which was formulated to deliver macronutrient and
micronutrient intake based on the intakes of 50th percentile population in the United
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States from NHANES report (6, 7). A strength of TWD, from a translation perspective, is
it represents the median composition of diets that Americans are eating (7).
To investigate the possible effects of PUFA on inflammation in physiologically
relevant diets, we formulated four diets on the TWD background. We reasoned that these
diets should not be too extreme, and thus decided to use the 90th and 10th percentiles of
intake for both n-6 and n-3 PUFAs. These diets allow us to investigate the individual
roles of both PUFA classes and cover the majority of diets in the US.
In this study, our hypothesis was high n-3 PUFA diet would reduce acute
inflammation caused by LPS, whereas high dietary n-6 PUFA would promote this
process. To induce acute inflammation, a sub lethal dose of LPS, delivered
intraperitoneally, was selected because a strong cytokine inflammatory response was
previously measured in this model (4). To evaluate the effect of these diets on
metabolism and the acute inflammatory response, we selected endpoints to measure
including weight gain, fat gain, cytokine levels, the lipid profile, and oxylipin
concentration. Because the main focus was inflammation, cytokine levels were the
primary endpoint to evaluate the overall responses. Also, we evaluated three possible
pathways (NF-κB, PPARs, and lipogenesis) via hepatic gene expression that may be
involved in the inflammatory responses.
Materials and Methods
Animals and diets
The TWD and PUFA modified diets were formulated using the principle of
nutrient density. First, we selected median daily intake levels from NHANES report.
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Next, we normalized median nutrient consumption data to calories consumed data to
calculate nutrient density measure (mass of nutrient per kcal per day). Finally, we
translated human nutrient intake information to a suitable rodent diet. To achieve this
step, relative contribution of total carbohydrates, proteins, and fats sources to total energy
consumed was calculated to establish the basic TWD. A mixture of oils was used to
design diets with different total overall PUFA and specific ratios. Casein and L-cysteine
were used for the protein portion of the diet. The nutrient density for noncaloric dietary
components was calculated based on median caloric intake per day from NHANES data
(7). The PUFA diets in this study were formulated to achieve n-6 (LA) and n-3 (ALA)
intakes at the 10th and 90th percentiles population according to NHANES by adjusting the
different oil composition in TWD. The components of four PUFA diets are summarized
in Table 2.1. The key parameters important for this study are underlined and italicized.
The targets for the lipid composition are shown at the bottom of the table. In using
different oil sources, the goal was to produce diets with defined n-6 and n-3 levels, while
keeping the saturated fatty acid composition similar across diet. Thus, the major
difference in the fatty acid composition, besides PUFA, should be in the monounsaturated
fatty acid content.
Thirty-two male weanling C57BL/6J mice (Jackson Labs, Bar Harbor, ME) were
randomly separated into four groups, with balanced initial weight across the groups, and
provided with one of the four diets with different PUFA levels (high n-6 & high n-3
(HH), high n-6 & low n-3 (HL), low n-6 & high n-3 (LH), and low n-6 & low n-3 (LL))
for 30 days. Mice were housed individually. Mice were weighed every four days and
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food intake was measured every other day. Body composition including body fat, lean,
and water was measured every two weeks for four weeks by MRI (EchoMRI-900TM,
Houston, TX, USA).
Acute inflammatory challenge, sacrifice, and sample collection
At day 29, all mice were injected with a sub lethal dose (5 mg/kg) of LPS solution
(0.5 mg/mL) via intraperitoneal injection. Twenty hours after injection, diets were
removed, and all mice were sacrificed four hours later via asphyxiation with CO2. Blood
was collected via cardiac puncture and pipetted into EDTA-lined tubes. Plasma was
isolated via centrifugation of the blood for 10 minutes at 1,000 × g. The supernatant
(plasma) was transferred to clean micro-centrifuge tubes, and red blood cells were kept
for fatty acid analysis. Liver and adipose tissue were collected and immediately frozen at
-80°C.
Plasma cytokine analysis
The plasma cytokine analysis was conducted following the manufacturer’s
instructions. Analysis of the cytokines in plasma was performed by 96-well Plate Assay
with Mouse Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore, Billerica, MA,
USA) (8). Standards were reconstituted in nanopure water and the antibody-immobilized
beads were dispersed by vortexing. Subsequently, 60 μL of the bead solution from each
antibody vial was mixed and brought final volume to 3.0 mL with assay buffer. Plasma
was reconstituted by adding 2.0 mL assay buffer to lyophilized plasma matrix. Working
standards were made by reconstituting the mouse cytokine standards with 250 μL
nanopure water. A dilution series was prepared six dilution levels of standard, and the
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blank standard was the assay buffer. A 96-well plate was cleaned with 200 μL of 1X
wash buffer. Next, 25 μL each standard including blank standards and quality control
standards were added into the wells with another 25 μL assay. After that, 25 μL matrix
solution was added. Then, 25 μL of sample was added. Finally, 25 μL of mixed beads
were mixed thoroughly and loaded to each well. The plate was sealed with aluminum foil
and placed on the shaker overnight at 2-8°C. After incubation, solution was removed
from the wells and each well was washed by 200 μL wash buffer twice. A handheld
magnet was used to set the magnetic beads in the plate. After washing the plate, 25 μL
detection antibodies were added into each well. The plate was incubated again on the
plate shaker for 1 hour at room temperature with aluminum foil covered. After
incubation, 25 μL Streptavidin-Phycoerythrin was added to each well. Plate was covered
with aluminum foil again and incubated on the plate shaker for another 30 minutes at
room temperature. After incubation, solution was gently removed from the well and then
was washed twice. Finally, 150 μL sheath fluid was loaded to all wells and suspended the
beads on the plate shaker for 5 minutes. Plate was sent to BioPlex system (Bio-Rad,
Hercules, CA, USA) to measure the concentration of cytokines.
Fatty acid profiling
Fatty acid profiling of red blood cells and diets
Frozen red blood cell pellets, or diet samples, were transferred to a 16 x 125 mm
screw-cap tube. Next, 0.7 mL of 10 M KOH solution and 5.3 mL methanol was added to
the tube. Samples were incubated at 55°C with shaking for 1.5 hours to saponify lipids.
After hydrolysis, tubes were cooled on ice, and 0.58 mL of 12 M H2SO4 solution was
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added to facilitate methylesterification. Samples were mixed thoroughly by inversion and
incubated at 55°C water bath shaker for 1.5 hours. After incubation, samples were cooled
on ice and 3 mL hexane was added with thorough mixing via vortex for 5 minutes.
Samples were centrifuged at 2,000 × g for 5 minutes and the hexane layer transferred to a
GC vial (9).
The fatty acid composition was determined by gas chromatography using a
Shimadzu GC-2010 (Shimadzu, Kyoto, Japan) with Agilent HP-88 column (100m x
0.25mm x 0.2μm; Agilent Technologies Inc., Santa Clara, CA, USA). Both injector and
detector temperature were set at 250°C. The initial column temperature was 153°C, held
for 2 minutes and subsequently temperature was increased to 174°C at a rate of 2.3°C per
minute. Then, it was held for 0.2 minute. Temperature was continuously increased to
210°C at a rate of 2.5°C per minute, and was held for 5 minutes. The split ratio was 25:1.
Column flow rate was 1.17 mL per minute. Fatty acids in the red blood cells or diets were
identified by comparing retention time with fatty acid methyl ester (FAME) standards.
Fatty acid profiling of hepatic tissue
Approximately 200 mg frozen hepatic tissue was ground under liquid nitrogen
with 50 μL of each internal standards including cholesterol esters (CE 15:0, 10 mg/mL),
diglycerides (DG 17:0, 10 mg/mL), triglycerides (TAG 19:1, 10 mg/mL), free fatty acids
(C21:0, 10 mg/mL), and phospholipids (PC 19:0, 10 mg/mL). Next, 4 mL of Folch
reagent (chloroform/methanol at 2:1 with Butylated hydroxytoluene (BHT)) was added to
sample powder. The mixture was agitated for 20 minutes to extract the lipids from liver
to organic phase. Then, vacuum filtration was applied to remove the protein residue.
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Next, 0.8 mL of 0.9% NaCl was added into the liquid collection and was then vortexed
for 2 minutes. Mixture was centrifuged at 2000 rpm at 4°C for 10 minutes. The organic
layer (lower phase) was transferred to a pre-weighed 4 mL vial. Then, the organic layer
was dried under nitrogen gas and weighed to calculate the weight of extracted lipids.
Lipids were re-dissolved with 200 μL Folch reagent.
Thin layer chromatography (TLC) plate was activated at 120°C for 10 minutes.
The plate was subsequently cleaned by running it in the TLC chamber with 100 mL of
solvent (chloroform/methanol at 1:1) and then plate was removed once solvent reached
two third of the plate. Twenty microliters of lipid extract and lipid standards mix
(including cholesteryl esters, triacylglycerols, free fatty acids, diacylglycerols,
phospholipid, choline) were loaded on TLC plate. TLC plate was placed in solvent
(hexane/diethyl ether/formic acid at 80:20:2) to separate lipid classes in each unknown
samples. TLC plate was removed from chamber once the solvent front reached the top
edge of plate. Premulin solution (0.05% premulin in acetone:water (8:2, v/v)) was
sprayed on the plate to visualize the lipid bands under UV light. Locations of lipid classes
were marked on the plate. Silica gel with each lipid class was scraped off from the plate
and collected.
Seven hundred microliters of 10 N KOH and 6.3 mL methanol was added into the
collection tubes. The mixture was placed in 55°C water bath shaker for 1.5 hours. Tubes
were cooled under tap water after incubation. Then, 580 μL of 24 N H2SO4 was added
into the tubes and mixed thoroughly. The tubes were placed back to the same water bath
shaker for another 1.5 hours. Samples were cooled down again after shaking. Two
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milliliters of hexane were added into the tubes and was vortexed for 5 minutes. Mixture
was centrifuged at 2,000 rpm for 10 minutes to separate the organic phase and aqueous
phase. Upper phase was transferred to 2 mL GC vials without disturbing the aqueous
layer. Organic phase was dried completely under nitrogen stream. Then, 100 μL of
hexane was added to re-dissolve the lipids samples for GC injection.

TABLE 2.1

Components of PUFA diets.

Diet / components (g/kg)
HH
HL
190.00 190.00
Casein
2.85
2.85
L-Csytine
230.00 230.00
Corn starch
70.00
70.00
Maltodextrin
261.07 261.07
Sucrose
56.43
54.12
Cocoa butter
23.10
29.70
Olive oil
61.88
13.20
Soybean oil
23.60
67.98
Corn oil
0.55
0.55
Cholesterol
30.00
30.00
Cellulose
35.00
35.00
Mineral mix
4.00
4.00
Sodium Chloride
10.00
10.00
Vitamin mix
1.40
1.40
Choline bitartrate
0.03
0.03
TBHQ, antioxidant
0.10
0.10
Food color
Macronutrient (% kcal)
50.00
50.00
Carbohydrate
15.40
15.40
Protein
34.50
34.50
Fat
PUFA (% kcal)
10.40
10.40
n-6 PUFA
1.10
0.40
n-3 PUFA
9.45
26.00
n-6 to n-3 PUFA ratio

LH
190.00
2.85
230.00
70.00
261.07
52.80
79.37
8.33
24.50
0.55
30.00
35.00
4.00
10.00
1.40
0.03
0.10

LL
190.00
2.85
230.00
70.00
261.07
52.80
85.50
16.50
10.20
0.55
30.00
35.00
4.00
10.00
1.40
0.03
0.10

50.00
15.40
34.50

50.00
15.40
34.50

5.10
1.10
4.64

5.10
0.40
12.75

HH, HL, LH, and LL represent high n-6 & high n-3 PUFA diet, high n-6 & low n-3
PUFA diet, low n-6 & high n-3 PUFA diet, and low n-6 & low n-3 PUFA diet,
respectively. TBHQ is tert-Butylhydroquinone.
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Fatty acids oxygenated compounds analysis
Mice hepatic sample was ground with 2 mL ethanol and oxylipin standards
(deuterated standard, 10 ng each). Standards included 4-hydroxy-2-hexenal (4-HHE)
CD3, 4-hydroxy-2-nonenal (4-HNE) CD3, TXB2 D4, 8-epiPGF2a D4, PGE2 D4, LTB4 D4,
(±)14,15-dihydroxy-eicosa-5,8,11,17-Tetraenoic Acid (14,15-DiHETE) D4. Then, 3 mL
methanol, 5 mL chloroform, and 4 mL nanopure water was added into the same tube.
After vortexing and centrifuge the samples, organic phase was collected. Then, another 5
mL chloroform was added to do the second extraction. After vortexing and centrifuging
the mixture, organic phase was collected again. Next, organic phase was evaporated and
sample was re-dissolved in 2 mL methanol to wash the sample. After methanol was
evaporated, 1 mL hexane with O-PFB-TMS was added into the sample tube. Sample tube
filled with nitrogen gas was placed in the shaker at room for 30 minutes with agitation.
After incubation, 5 mL hexane and 60 μL H2SO4 was added into the tube. Supernatant
was collected after thorough mixing. Sep-Pak C18 column was used to purify the
samples. Column was washed by 3 mL methanol then followed by 6 mL nanopure water.
The samples were then loaded on the column. Column was washed again by 9 mL pH 3.5
HCl solution then followed by 4 mL nanopure water. Finally, column was washed by 5
mL hexane. The sample was eluted by 9 mL of methyl formate. After evaporating the
solvent, samples were re-dissolved in the injection solvent for LC-MS/MS.
Gene expression analysis
The genes which we measured for mice inflammatory responses include 18s
rRNA (for normalization), Acaca, Acox1, Ccl2, Ccl3, Cpt-2, CRP, Dgat-2, Elovl-5, Fasn,
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Hmgb-1, Ikb-α, IL-1α, IL-1β, IL-6, Me-1, NF-κB-1, Inhibitor of NF-κB-β (NF-κbib),
Ppar-α, Ppar-β, Scd-1, Srebp-1, and Tnf-α.
The RNeasy tissue mini kit (QIAGEN, Hilden, Germany) was used for RNA
extraction from mice tissue. Before RNA extraction, working wash buffer solution was
made from wash buffer RPE by mixing with 4 volumes of ethanol. Also, 350 μL
2-mercaptoethanol was added to the QIAzol lysis reagent (QIAGEN, Hilden, Germany).
Working area was cleaned with 70% ethanol and RNaseZap (Invitrogen, Waltham, MA,
USA) to remove RNase contamination.
Liver RNA extraction
Approximately 20 mg frozen hepatic tissue was ground under liquid nitrogen.
After the liquid nitrogen evaporated, 600 μL lysis reagent was added, and samples were
homogenized with a pestle until tissue was totally disrupted and lysed. Lysate was
incubated at 4°C for one hour and then was loaded onto a QIAshredder spin column
placed in a 2 mL collection tube. Samples were centrifuged at 12,000 rpm for 2 minutes
at 4°C. Next, 600 μL 70% ethanol was added to the lysate and mixed thoroughly. The
lysate/ethanol mixture was incubated at 4°C overnight. Subsequently, 600 μL of sample
was transferred to spin cartridge, and centrifuged at 12,000 rpm for 15 seconds at room
temperature. Steps were repeated till all sample solution was loaded. Next, the spin
cartridge was washed with 350 μL wash buffer I. Subsequently, 100 μL DNase I working
solution was added to column. After quick centrifugation, the column was held at room
temperature for 20 minutes. The spin cartridge was washed again and was placed into a
new collection tube. Then, the spin cartridge was washed by 500 μL working wash buffer
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solution twice and placed into a recovery tube. Finally, 50 μL RNase-free water was
added to the spin cartridge to cover the whole surface of membrane. Spin cartridge was
centrifuged at 12,000 rpm for 2 minutes after short incubation to collect the RNA in the
recovery tube.
Adipose RNA extraction
Approximately 100 mg frozen adipose tissue was ground under liquid nitrogen.
Steps for lysis, homogenization and loading samples to the spin column were same as
described in the liver RNA extraction. Next, 200 μL chloroform was added to lysate and
spin column was shaken vigorously for 15 seconds. Spin column was centrifuged for 15
minutes at 12,000 rpm at 4°C after short sitting under room temperature. Aqueous phase
was then transferred to a fresh tube. Approximate 600 μL of 70% ethanol was added to
the sample, and then sample was mixed thoroughly by vortexing. The remaining
procedures were same as described in the liver RNA extraction.
Measurement of RNA concentration
Nanodrop 1000 spectrometer (Thermo Scientific, Walthem, MA, USA) was used
for measuring RNA concentration from extraction. RNA-40 was chosen on the software.
About 2 μL nanopure water was loaded on the clean lower measurement pedestal to zero
the absorbance. Then, 2 μL RNA sample was loaded to get the reading of RNA
concentration.
RNA to cDNA conversion
Based on the concentration of RNA measured by nanodrop spectrometer, RNA
concentration was adjusted to 2000 ng/μL in 9 μL solution by RNase-free water. Next, 11
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μL RT master was mixed with 9 μL RNA sample in the 200 μL micro-centrifuge tube.
The micro-centrifuge tube was then placed in the PCR cycler. RT reaction was held at
37°C for 60 minutes, and then terminated at 95°C for 5 minutes followed by cooling at
4°C.
Real Time quantitative PCR
cDNA samples were pre-amplified before real time quantitative PCR for 14
cycles to increase the original concentration. Fluidigm 48.48 chip (Fluidigm, San
Francisco, CA, USA) was applied for real time quantitative PCR. Control line fluid was
injected into each accumulater on the chip. Next, the chip was placed into the Integrated
Fluidic Circuit (IFC) Controller MX to prime the control line fluid into the chip. In the
meantime, 3 μL 20x TaqMan Gene Expression Assay (Applied Biosystems, Waltham,
MA, USA) and 3 μL 2x Assay Loading Reagent (Fluidigm, San Francisco, CA, USA)
was mixed in a 96 well microplate. Also, 180 μL TaqMan Universal PCR Master Mix
(2x) (Applied Biosystems, Waltham, MA, USA) and 18 μL 20x GE Sample Loading
Reagent (Fluidigm, San Francisco, CA, USA) was mixed to prepare pre-mix solution.
After that, 3.3 μL pre-mix solution and 2.7 μL cDNA sample was mixed in a 96 well
microplate by multi-channel pipette. After chip was primed, 5 μL of each gene primer
mix was loaded in the assay inlets. Also, 5 μL of each sample mix was loaded in the
sample inlets. Then, the chip was placed back to the IFC Controller MX to load the
samples and assays into the chip. After process was finished, chip was placed on Biomark
data collection system (Fluidigm, San Francisco, CA, USA) to run real time quantitative
PCR.
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Gene expression data analysis
The data from real time quantitative PCR is shown as Ct value (threshold cycle
for gene amplification) for each gene from each sample. The analytical method used in
this study to present relative gene expression levels is comparative Ct method and is
known as the known as 2-ΔΔCt method (10, 11). In PCR, the gene amplification is
described as follows.
Xn = X0 * (1+Ex)n
Where Xn is the amount of target genes at cycle n of PCR reaction; X0 is the initial
amount of target genes; Ex is the efficiency of gene amplification; n is the number of
PCR cycles.
Once threshold cycle (Ct) is reached, the amount of target genes can be described
as follow.
Xt = X0 * (1+Ex)Ct,x=Kx
Where Xt is the amount of genes at the number of cycle reaches threshold; Ct,x is the
threshold cycle for target gene (x) amplification; Kx is a constant.
Similar as target genes, a reference gene (18s rRNA) is used in the same
calculation model.
Rt = R0 * (1+ER)Ct,r=KR
Where Rt is the amount of reference gene at the number of cycle reaches threshold; R0 is
initial amount of reference gene; ER is the efficiency of reference gene amplification; Ct,r
is the threshold cycle for reference gene (R) amplification; KR is a constant.
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Although the value of Xt and Rt can be affected by many factors, it is assumed
that the efficiencies of target and reference genes are the same under same PCR
processing (Ex=ER=E). The relative expression level of target gene compared with
reference gene can be written as follow.
Xt/Rt = X0/R0 * (1+E) Ct,x-Ct,r =K
Here, ΔCt is calculated by Ct,x-Ct,r. Thus, the equation can be written as follow.
XN * (1+E) ΔCt = K
Where XN is normalized initial amount of target gene (X0/R0); ΔCt is the difference of
threshold between target gene and reference gene. Transform the equation to get new
expression.
XN = K * (1+E)-ΔCt
If there is a control group in the experiment, XN could be normalized to control
group to calculate the relative increment of target gene in the treatment group compared
with control group. The equation can be rewritten as follow (t and c means treatment and
control group in the equation).
XN,t/XN,c = K * (1+E) –ΔCt,t-(-ΔCt,c) = K * (1+E)-ΔΔCt
Here –ΔΔCt = - (ΔCt,t - ΔCt,c). ΔΔCt is obtained by normalizing to control group. In this
study, we used average ΔCt in the dietary group LH as control since it is expected to have
the lowest inflammatory gene expression level based on published researches.
As we mentioned that PCR process is exponential amplification from initial
amount of gene, the amount of gene after amplification could be calculated as 2-ΔΔCt.

54
2-ΔΔCt represents the fold changes of target genes compared to reference gene and control
group.
By using this method, we could see that fold changes of genes in the control
group are supposed to be very close to one (20 = 1). However, because of the high
variation in the biological samples, –ΔΔCt from each sample could be somehow away
from zero since each sample will not be exact same as average under same treatment.
This variation will lead to average of 2-ΔΔCt being away from one.
Statistical analysis
A 2×2 factorial design was used to evaluate the main effects of n-6 PUFAs and n3 PUFAs with the interaction effect based on n-6 to n-3 PUFA ratio on inflammatory
responses. Shapiro-Wilk test was used to test the normality of data (logarithm
transformation was done if the original data was not normal distributed). A False
discovery rate (FDR) was applied and was set at 0.05. The FDR reduces the risk of false
positives by adjusting the p-values due to multiple comparisons. Analyses were
performed with SPSS software version 19 (IBM Corporation, Armonk, New York, USA)
and SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Data was reported as mean ± standard
deviation.
Results
Diet composition
The main fatty acid compositional parameters of the diets are shown in Table 2.2. In
general, the measured values were very close to the targets. Thus, there was ~10% n-6
PUFA in the HH and HL diets, and ~5% in the LH and LL diets. For n-3 PUFA, the
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values were close to 1% in the HH and LH diets, and 0.4% in the HL and LL diets. Due
to the high n-6 content, both the HH and HL diets contained over 10% total PUFA,
whereas LH and LL diets were lower than 6.2%. Importantly, all diets contained a
similar amount of saturated fatty acids (~10.5%), and the balance was achieved by
changing the monounsaturated fatty acid content. This is important as dietary saturated
fatty acids may affect inflammatory processes independently.

TABLE 2.2

Measured lipid values for experimental diets.

HH

HL

LH

LL

10.5 ± 0.1
17.8 ± 0.1
6.2 ± 0.1
5.1 ± 0.1
1.1 ± 0.1
4.6

10.4 ± 0.1
18.8 ± 0.1
5.4 ± 0.1
4.9 ± 0.1
0.4 ± 0.1
11.6

% kcal
Saturates
MUFA
PUFA
n-6
n-3
n-6 to n3 ratio

10.6 ± 0.1
12.1 ± 0.1
11.8 ± 0.1
10.7 ± 0.1
1.1 ± 0.1
9.6

10.1 ± 0.1
13.6 ± 0.1
10.6 ± 0.1
10.2 ± 0.1
0.4 ± 0.1
24.0

HH, HL, LH, and LL represent high n-6 & high n-3 PUFA diet, high n-6 & low n-3
PUFA diet, low n-6 & high n-3 diet, and low n-6 & low n-3 PUFA diet, respectively.
MUFA represents monounsaturated fatty acids.

Food intake, body weight, and body fat composition
Mice fed with high n-6 PUFA diets (HH and HL) had a significantly higher food
intake (Fig. 2.1). In addition, mice fed the high n-6 diets gained significantly more weight
(Fig. 2.2). Furthermore, mice fed the high n-6 diets had significantly higher fat gain (Fig.
2.3). Interestingly, mice fed the low n-3 diets gained less lean weight than mice fed the
high n-3 diets (Fig. 2.4).
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Fatty acid profile of red blood cells
The red blood cell (RBC) PUFA content is shown in the Table 2.3. The three
dominant PUFAs are 18:2n6, 20:4n6, and 22:6n3. According to the 2x2 ANOVA with
adjustment for the FDR, n-6 intake affected concentration of 18:2n6, 20:3n6, 22:5n6,
22:5n3 and 22:6n3. With the exception of 20:3n6, the results indicate that more n-6
increased both 18:2n6 (present in the diet) as well as its elongation and desaturation
products, and reduced n-3 elongation and desaturation products. The surprise effect is
that the high n-6 diets decreased the amount of 20:3n6 relative to the low n-6 diets. On
the other hand, high n-3 intake affected levels of 20:2n6, 22:5n6, 20:5n3, 22:5n3, and
22:6n3. There were no effects from an n-6 to n-3 PUFA interaction. The n-3 index, which
is the sum of the percentage of EPA and DHA in RBCs, and which has been correlated
with several health parameters in humans, was higher in the LH group compared to the
others. Since mice in the LH diet group had higher DPA and DHA than mice in the HH
group, it appears reducing the n-6 intake promotes elongation of linolenic acid.
Plasma cytokine analysis (post-LPS challenge)
Cytokines analyzed in plasma included IL-1α, IL-1β, IL-3, IL-5, IL-6, IL-10, IL12, IL-17, IFN-γ, MCP-1, MIP-1α, Granulocyte-macrophage colony-stimulating factor
(GM-CSF), Keratinocyte-derived chemokine (KC), TNF-α, RANTES. As the data was
not normally distributed, a logarithmic transformation was applied. Using 2x2 factorial
analysis, the differences (p-value less than 0.05) between groups are shown in the Table
2.4. There was an increase in the concentration of IL-1α, IL-1β, IL-10, IL-17, MIP-1α,
and RANTES that was driven by the n-3 PUFA content of the diet. On the other hand,
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higher MCP-1, TNF-α, and KC levels were affected by n-6 PUFA and n-3 PUFA
interaction (high n-3 and low n-6 PUFA in the diet). The higher IL-6 and IFN-γ
concentration was led by n-3 PUFA and n-6 x n-3 PUFA interaction (high n-3 and low n6 PUFA in the diet). However, when a False Discovery Rate (FDR) adjustment for
multiple testing was applied at a p value of 0.05 (to reduce type I error), there were no
significant differences for any cytokines.
Fatty acid profile of liver
The lipid composition of the liver tissue was measured to investigate the effects of
dietary fat, and to determine if there is a relationship with both gene expression and
oxylipin production. The total lipid content of each major lipid classes, phospholipids
(PL), triacylglycerol (TAG), diglycerides (DG), free fatty acids (FFA) and cholesterol
esters (CE) are shown in the Table 2.5. There was no difference between dietary groups
in overall PC, TAG, and DG. On the other hand, n-6 PUFA intake affected both the FFA
and CE levels in the liver.
In liver, PL are the primary lipid class from which PUFA are cleaved in order to
generate eicosanoids (12), and TAG may also provide substrates. The PUFA profiles of
PL and TAG are shown in Tables 2.6 and 2.7. In the PL profile, the levels of 18:2n6 and
20:2n6 are significantly higher in the high n-6 PUFA groups. Conversely, for the n-3
diets there were higher 18:3n3 levels. EPA was affected by both low dietary n-6 and high
dietary n-3. From TAG PUFA profile, higher 20:4n6 level was driven by both high n-6
PUFA content and low n-3 PUFA content.
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Analysis of oxygenated compounds of fatty acids
Oxygenated fatty acids (oxylipins) are intermediates in the inflammatory process
and are metabolites of the long chain n-6 and n-3 fatty acids. Hepatic oxylipins are shown
in Table 2.8. PGE2, a major oxylipin derived from AA, was higher in the HL group
(affected by high n-6 PUFA content and low n-3 PUFA content) and there was more 14OH DHA according to the n-3 content of the diet. However, these differences were not
significant after adjusted p-value for multiple comparisons.
Tissue gene expression
The results of hepatic gene expression are shown in Table 2.9. Expression levels
were normalized to the 18s rRNA gene in the LH dietary group, which we hypothesized
to have lowest gene expression level among all groups. Next, the fold change of each
gene in the other dietary groups was compared. Generally, the fold change of genes in the
control is supposed to be close to one when data variance is small. However, the
variances in our data were large which results in the fold change in the control group (LH
group) not being exactly one. A 2x2 factorial analysis was run to access the effects of
dietary PUFA on gene expression across all dietary groups. There were increases in
expression of genes associated with lipogenesis such including Acaca, Dgat2, Elovl5,
Me1, and Srebp-1, which were driven by the high n-6 diets. Furthermore, genes related to
NF-κB pathway, Ccl2, Ccl3, IL-1b, IL-6, nfkb1, and Tnf-α also had increased expression
in the high n-6 diets. For PPAR-α pathway, Acox1, Cpt-2, Hmgb1, and Ppar-α were
enhanced in the mice fed with high n-6 PUFA diet. On the other hand, dietary n-3 PUFA
did not show any effects on lipogenesis, NF-κB, and PPAR-α related gene expression.
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The mice fed with HL diet also showed significantly higher lipogenesis related Fasn
expression level than those fed with LL diet.
Hepatic cholesterol esters
While there were no differences in the content of PL, TAG or DG in the liver,
there were large differences in the CE and FFA content. The fatty acid profile of CE is
listed in the Table 2.10. The dominant fatty acid in the cholesterol ester fraction is C14:0
(myristic acid), and it makes up over 50% of the total fatty acids. The n-6 content of the
diet appears to lower several fatty acids in the cholesterol esters including 14:0, 14:1n5,
16:0, 16:1n7, 18:1n9 and 20:3n6.
The hepatic free fatty acid profile is shown in Table 2.11. Like the CE fraction,
there are several differences driven by the n-6 content of the diet, but no independent
effects of n-3 fatty acids. There are significant differences in 12:0, 16:0, 17:0, 18:0 and
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FIGURE 2.1 Food intake across the different dietary groups. The data represents mean
± SD. Means with different superscripts are significantly different (p<0.05).
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FIGURE 2.2 Weight gain across the different dietary groups. The data represents mean
± SD. Means with different superscripts are significantly different (p<0.05).
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FIGURE 2.3 Fat gain across the different dietary groups. The data represents mean ±
SD. Means with different superscripts are significantly different (p<0.05).
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FIGURE 2.4 Lean gain across the different dietary groups. The data represents mean ±
SD. Means with different superscripts are significantly different (p<0.05).
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TABLE 2.3

Fatty acid composition of mice red blood cells from four PUFA diets.

Diets
HL

LH

LL

Adjusted p value (FDR)
n-6
n-3
Interaction

PUFA

HH

C18:2 n6 (LA)
C20:2 n6
(Eicosadienoic
acid)
C20:3 n6
(DGLA)
C20:4 n6
(AA)
C22:4 n6
(Adrenic acid)
C22:5 n6
(Osbond acid)

12.26±3.44

Omega-6
13.38±2.71 9.14±0.71

9.33±2.19

0.01

NS

NS

0.35±0.06

0.38±0.06

0.27±0.04

0.38±0.11

NS

0.05

NS

1.37±0.29

1.48±0.23

1.83±0.16

1.63±0.27

0.02

NS

NS

13.89±2.56

16.20±1.31

13.70±1.75

14.03±2.20

NS

NS

NS

1.45±0.41

1.59±0.38

1.22±0.23

1.27±0.31

NS

NS

NS

0.80±0.26b

1.26±0.24a

0.57±0.07b

0.80±0.16b

<0.01

<0.01

NS

Omega-3
C18:3 n3
(ALA)
C20:5 n3
(EPA)
C22:5 n3
(DPA)
C22:6 n3
(DHA)
n-3 index

0.35±0.16

0.21±0.05

0.35±0.12

0.22±0.07

NS

0.03

NS

0.68±0.39

0.35±0.13

1.00±0.28

0.51±0.14

NS

<0.01

NS

0.85±0.18b

0.68±0.19b

1.22±0.25a

0.81±0.16b

0.02

<0.01

NS

5.77±0.69b

5.68±0.59b

7.35±0.71a

5.67±1.08b

0.05

0.03

NS

6.45±1.08b

6.03±0.72b

8.34±0.99a

6.17±1.22b

<0.01

<0.01

0.01

The n-3 index is the sum of EPA and DHA. The data represents mean (percentage) ± SD.
Means with different superscripts are significantly different (p<0.05). NS means not
significantly different.
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TABLE 2.4 Log(10) transformed plasma cytokine concentration across four dietary
groups.

p-value

Cytokines
(pg/mL)

HH

HL

LH

LL

IL-10
IL-17
IL-1α
IL-1β
MIP-1α
RANTES
IFN-γ
IL-6
KC
MCP-1
TNF-α
IL-3
IL-5
IL-12
GM-GSF

2.96±0.33
2.61±0.87
2.23±0.38
1.69±0.34
2.80±0.33
3.89±0.84
2.86±0.67
4.44±0.44
4.44±0.20
4.05±0.45
2.01±0.38
0.46±0.48
1.49±0.46
1.50±0.38
2.52±0.12

2.83±0.26
2.12±0.73
1.93±0.24
1.34±0.28
2.61±0.33
3.47±0.36
2.67±0.55
4.54±0.21
4.45±0.13
4.13±0.19
2.04±0.13
0.41±0.13
1.49±0.26
0.97±0.46
2.47±0.19

2.86±0.20
2.91±0.17
2.19±0.34
1.68±0.24
2.84±0.30
4.19±0.53
3.54±0.32
4.70±0.04
4.54±0.09
4.32±0.16
2.20±0.17
0.41±0.31
1.76±0.27
1.52±0.29
2.57±0.18

2.52±0.22
1.70±1.15
1.88±0.31
1.26±0.50
2.38±0.44
3.09±0.72
2.04±1.29
3.71±0.84
4.14±0.39
3.69±0.47
1.63±0.50
0.26±0.49
1.36±0.21
1.53±0.38
2.41±0.18

n-6

n-3

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

0.03
0.01
0.02
0.01
0.04
<0.01
0.01
0.04
NS
NS
NS
NS
NS
NS
NS

Interac
tion
NS
NS
NS
NS
NS
NS
0.05
0.01
0.04
0.02
0.04
NS
NS
NS
NS

The data represents mean ± SD. NS means not significantly different.

TABLE 2.5

Total liver lipid compositions from all lipid classes.

Diets
Fatty acid
(mg/g)
PL
TAG
DG
FFA
CE
Total

HH

HL

LH

LL

61.03±5.48
24.42±15.49
0.91±0.36
0.44±0.10
16.26±4.62
102.66±14.79

62.13±3.16
28.59±11.00
0.84±0.20
0.48±0.08
14.30±3.77
107.33±17.30

60.67±8.74
19.70±9.46
1.06±0.37
0.81±0.43
20.35±6.37
102.59±17.53

63.37±4.88
31.27±10.99
1.13±0.29
0.82±0.29
25.92±3.28
122.51±18.33

p values for 2*2
ANOVA
Interac
n6
n3
tion
NS
NS
NS
NS
NS
NS
NS
NS
NS
<0.01
NS
NS
<0.01
NS
NS
NS
NS
NS

The data represents mean ± SD. NS means not significantly different.
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TABLE 2.6

PL PUFA composition in liver.

Adjusted p value (FDR)

Diets
PUFA (mg/g)

HH

HL

LH

LL

n-6

n-3

Intera
ction

C18:2 n6 (LA)

9.44±0.99

9.95±0.37

7.99±1.55

7.67±0.76

<0.01

NS

NS

C18:3 n6 (GLA)
C20:2 n6
(Eicosadienoic
acid)
C20:3 n6
(DGLA)
C20:4 n6 (AA)

0.12±0.03

0.13±0.03

0.09±0.04

0.09±0.04

NS

NS

NS

0.14±0.03

0.14±0.02

0.09±0.02

0.10±0.02

<0.01

NS

NS

0.61±0.16

0.59±0.11

0.76±0.35

0.79±0.16

NS

NS

NS

10.18±1.70

11.19±0.80

9.52±1.60

10.61±0.61

NS

NS

NS

C18:3 n3 (ALA)

0.15±0.09

0.07±0.02

0.19±0.05

0.08±0.02

NS

<0.01

NS

C20:5 n3 (EPA)

0.15±0.03

b

0.06±0.01

b

0.38±0.10

a

0.16±0.04

b

<0.01

<0.01

NS

C22:5 n3 (DPA)

0.25±0.11

0.23±0.04

0.23±0.12

0.23±0.10

NS

NS

NS

C22:6 n3 (DHA)

7.32±0.57

6.47±0.95

6.76±1.66

7.17±1.15

NS

NS

NS

The data represents mean ± SD. Data with different superscripts are significantly
different (p<0.05). NS means not significantly different.
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TABLE 2.7

TAG PUFA composition in liver.

Diets
PUFA (mg/g)
C18:2 n6
(LA)
C18:3 n6
(GLA)
C20:2 n6
(Eicosadienoi
c acid)
C20:3 n6
(DGLA)
C20:4 n6
(AA)
C18:3 n3
(ALA)
C20:5 n3
(EPA)
C22:5 n3
(DPA)
C22:6 n3
(DHA)

Adjusted p value (FDR)
Intera
n-6
n-3
ction

HH

HL

LH

LL

5.78±4.26

6.89±2.67

2.69±1.56

4.26±1.82

NS

NS

NS

0.11±0.08

0.14±0.04

0.05±0.03

0.09±0.04

NS

NS

NS

0.06±0.02

0.08±0.05

0.04±0.01

0.08±0.04

NS

NS

NS

0.15±0.04

0.22±0.07

0.12±0.03

0.17±0.05

NS

NS

NS

0.46±0.16a,b

0.63±0.17a

0.21±0.08c

0.39±0.09b,c

<0.01

0.03

NS

0.31±0.24

0.18±0.07

0.25±0.16

0.19±0.10

NS

NS

NS

0.08±0.04

0.05±0.02

0.08±0.04

0.05±0.03

NS

NS

NS

0.14±0.08

0.10±0.03

0.12±0.06

0.09±0.03

NS

NS

NS

0.76±0.32

0.64±0.19

0.61±0.28

0.63±0.16

NS

NS

NS

The data represents mean ± SD. Data with different superscripts are significantly
different (p<0.05). NS means not significantly different.
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TABLE 2.8

Oxylipins in the liver.

Diets
Oxylipin
(ρmol/g)
15-HETE
12-HETE
5-HETE
4-OH DHA
7-OH DHA
14-OH DHA
17-OH DHA
11-OH DHA
PGE2
PGF2α
TXB2

HH

HL

LH

LL

3.05±1.71
21.04±20.37
0.95±0.73
0.77±0.58
0.13±0.04
3.60±3.33
1.44±0.85
0.30±0.14
0.12±0.04b
0.21±0.07
0.24±0.21

2.00±1.51
8.23±9.72
1.07±0.98
0.77±0.63
0.08±0.04
1.18±1.05
0.67±0.37
0.19±0.14
0.37±0.23a
0.25±0.17
0.19±0.20

1.13±1.31
9.81±6.00
0.49±0.48
0.59±0.70
0.08±0.05
2.87±1.58
0.79±0.67
0.15±0.08
0.10±0.06b
0.24±0.14
0.35±0.30

1.29±1.76
4.28±2.92
0.82±1.28
0.64±0.77
0.09±0.06
1.12±0.94
0.86±0.78
0.15±0.08
0.15±0.10b
0.26±0.26
0.15±0.11

Adjusted p value
(FDR)
Interac
n-6
n-3
tion
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

Abbreviation: 15-hydroxyeicosatetraenoic acid (15-HETE), 12-hydroxyeicosatetraenoic
acid (12-HETE), 5-hydroxyeicosatetraenoic acid (5-HETE), 4-hydroxy-docosahexaenoic
acid (4-OH DHA), 7-hydroxy-docosahexaenoic acid (7-OH DHA), 14-hydroxydocosahexaenoic acid (14-OH DHA), 17-hydroxy-docosahexaenoic acid (17-OH DHA),
11-hydroxy-docosahexaenoic acid (11-OH DHA), prostaglandin E2 (PGE2),
prostaglandin F2α (PGF2α), thromboxane B2 (TXB2). The data represents mean ± SD.
Data with different superscripts are significantly different (p<0.05). NS means not
significantly different.
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TABLE 2.9

Hepatic gene expression.

Diets
Genes (log2
fold change)

HH

HL

Adjusted p value (FDR)
LH

LL

n-6

n-3

Interaction

0.49±0.31
0.74±0.35
2.46±2.11
0.40±0.31
0.76±0.35
0.46±0.44
0.67±0.26
0.61±0.32
0.45±0.33

0.03
0.03
NS
NS
0.02
0.03
0.02
NS
0.02

NS
NS
NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS

1.46±1.04
0.76±0.59
1.81±1.01
1.19±1.28
1.78±1.00
0.67±0.25
1.43±0.87a,b 0.79±0.46b
1.36±1.01
1.09±0.70
1.92±1.21
1.06±0.75
1.21±0.59
0.82±0.32
PPAR-α pathway
1.69±1.01
1.26±0.52
1.51±0.94
1.53±0.82
1.26±0.70
0.53±0.70
2.06±1.14
1.24±0.59
1.07±0.37
0.99±1.10

0.03
0.04
0.03
NS
0.04
NS
0.04

NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
0.03
NS
NS
NS

0.03
0.03
0.03
0.03
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

NF-κB pathway
Ccl2
Ccl3
CRP
IL-1α
IL-1β
IL-6
Nfκb1
Nfκbib
Tnf- α

2.26±1.28
2.15±1.04
5.50±7.52
2.61±2.05
2.67±1.48
3.77±2.93
1.52±0.82
1.30±1.31
2.03±1.10

1.86±1.26
1.49±0.80
6.80±7.30
1.82±0.95
1.69±0.82
1.75±1.14
1.68±0.77
1.10±0.57
1.55±0.93

Acaca
Dgat2
Elovl5
Fasn
Me1
Scd-1
Srebp-1

1.77±1.41
2.23±1.69
2.52±1.12
1.09±0.48a,b
1.46±0.71
1.61±0.93
1.68±0.92

3.44±2.29
3.44±1.81
2.20±1.12
2.05±0.78a
2.59±0.95
2.19±0.85
1.57±0.48

Acox1
Cpt-2
Hmgb1
Ppar-α
Ppar-d

1.64±0.63
1.82±0.93
2.37±1.99
2.23±0.94
1.50±1.40

2.83±1.10
3.02±1.12
2.40±1.39
3.22±1.75
0.95±0.39

1.56±1.07
1.39±0.92
3.20±3.46
1.10±0.46
1.50±0.78
1.47±1.01
1.16±0.56
1.29±1.03
1.27±0.83
Lipogenesis

The data represents mean ± SD. Data with different superscripts are significantly
different (p<0.05). NS means not significantly different.
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TABLE 2.10

Fatty acid content of CE in the liver.

Diets
PUFA
C14:0
(Myristic
acid)
C14:1 n5
(Myristoleic
acid)
C16:0
(Palmitic
acid)
C16:1 n7
(Palmitoleic
acid)
C18:0
(Stearic acid)
C18:1 n9
(Oleic acid)
C18:2 n6
(LA)
C18:3 n3
(ALA)
C20:3 n6
(DGLA)
C20:4 n6
(AA)

p values for 2*2 ANOVA
Intera
n-6
n-3
ction

HH

HL

LH

LL

9.92±3.39

9.27±2.56

12.17±3.81

15.09±2.10

<0.01

NS

NS

1.06±0.36

0.89±0.29

1.10±0.28

1.43±0.32

0.04

NS

NS

1.40±0.34

1.11±0.18

1.48±0.44

1.85±0.36

<0.01

NS

NS

0.21±0.29

0.09±0.07

0.27±0.16

0.38±0.24

0.05

NS

NS

0.65±0.36

0.40±0.11

0.65±0.41

1.02±0.52

NS

NS

NS

0.82±0.47

0.64±0.53

2.09±1.19

3.02±1.90

<0.01

NS

NS

0.33±0.21

0.27±0.22

0.29±0.12

0.40±0.19

NS

NS

NS

0.04±0.03

0.03±0.02

0.07±0.05

0.05±0.03

NS

NS

NS

0.06±0.03

0.06±0.02

0.11±0.07

0.13±0.07

<0.01

NS

NS

0.17±0.06

0.18±0.07

0.11±0.04

0.19±0.07

NS

NS

NS

The data represents mean ± SD. NS means not significantly different.
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TABLE 2.11

Fatty acid content of FFA in the liver.

Diets
PUFA
C12:0
(Lauric
acid)
C14:0
(Myristic
acid)
C15:0
(Pentadecan
oic acid)
C16:0
(Palmitic
acid)
C17:0
(Margaric
acid)
C18:0
(Stearic
acid)
C18:1 n9
(Oleic acid)
C18:2 n6
(LA)

p values for 2*2 ANOVA
Intera
n-6
n-3
ction

HH

HL

LH

LL

0.02±0.01

0.03±0.01

0.04±0.02

0.05±0.02

<0.01

NS

NS

0.04±0.02

0.05±0.03

0.08±0.07

0.08±0.07

NS

NS

NS

0.01±0.00

0.01±0.00

0.02±0.02

0.01±0.01

NS

NS

NS

0.11±0.04

0.11±0.03

0.22±0.13

0.22±0.08

<0.01

NS

NS

0.02±0.01

0.02±0.01

0.03±0.01

0.04±0.01

<0.01

NS

NS

0.09±0.04

0.11±0.06

0.15±0.06

0.17±0.06

0.02

NS

NS

0.03±0.01

0.02±0.01

0.05±0.05

0.04±0.02

0.04

NS

NS

0.01±0.01

0.01±0.00

0.01±0.01

0.01±0.01

NS

NS

NS

The data represents mean ± SD. NS means not significantly different.

Discussion
In this project, our goal was to investigate whether modifying the PUFA content
of the TWD, within physiological ranges, would affect acute inflammation induced by a
sublethal dose of LPS. Mice fed the high n-6 PUFA diets had significantly higher food
intake and gained more weight. The increased weight was due to both fat and lean tissue.
However, the increased mass in mice fed the HL diet was only due to increased fat. This
suggests that the HH diet promotes greater weight through growth while the HL diet
appears to promote increased weight via adipogenesis. A possible mechanism is that
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dietary PUFA enhance muscle mammalian target of rapamycin (mTOR) pathway to
increase lean gain (13). On the other hand, it has been shown that high n-6 to n-3 PUFA
ratio decreases long-chain n-3 PUFA in humans. This, in turn, has been shown to
enhance the SREBP-1c to PPAR-α ratio, favor lipogenesis over fatty acid oxidation (14,
15).
The fatty acid composition of red blood cells is a good indicator of dietary fatty
acid intake (16), and in this study was used to monitor how the different diets affected
their composition. The main focus was on AA, EPA, and DHA because they are the
precursors of eicosanoids which are thought to drive inflammatory responses directly.
According to the data, higher levels of EPA and DHA were driven by high intake of n-3
PUFA (ALA). Moreover, DHA content increased under low n-6 PUFA diet. AA, major
precursor for n-6 PUFA related eicosanoids, surprisingly, was not affected by dietary
PUFA contents and ratios. This result implies that there is a competitive process for the
elongation and desaturation of ALA to EPA and DHA, as a lower level of n-6 PUFA in
the diet resulted in more DHA, when similar amounts of ALA were fed. This result is
consistent with the inhibition of LA on the biosynthesis of n-3 long chain PUFAs via
competing the rate-limiting enzymes of long chain PUFA synthesis such as Δ5 and Δ6
desaturase (17-20).
An interesting biomarker changed by the completion for elongation and
desaturation of ALA is the n-3 index. It was higher in the LH group than the other groups.
In humans, the n-3 index has shown a correlation with susceptibility to heart disease, with
a value over 8% being cardio protective, while a value less than 4% is consider a risk

70
factor (21). Mice in LH diet had a n-3 index significantly higher than mice fed the other
diets, and at 8.34%, this level would be associated with protection against the
development of CHD in humans. Collectively, these data suggest that the overall body
long chain PUFA is affected by the levels fed in the diets, and may affect downstream
inflammatory processes.
Cytokines were the primary endpoints measured to assess the inflammatory
response to the LPS injection. From cytokine analysis, after adjusting the p-value for
multiple tests, we found there were no differences in the cytokines. Although there were
some significant differences in the 2x2 factorial design, the effect was not sufficiently
robust to withstand correction for multiple tests. Thus, the PUFA contents and n-6 to n-3
PUFA ratios did not affect the mice plasma cytokine levels. Although Schmocker et al.
(22) reported that n-3 PUFAs could alleviate acute inflammation caused by LPS, the n-6
to n-3 PUFA ratio (AA:EPA) in the mice was very extreme (at 1:1). In our study, by
feeding our PUFA diets, the AA to EPA ratio in the RBC was from 14:1 to 46:1 which is
lower than their study, and more importantly, closer to levels in humans consuming a
Western Diet. A study done by Pluess et al. (23) found that dietary n-3 PUFA blunted
LPS-induced acute inflammation. However, they used fish oil which is very high in EPA
and DHA. Diets such as these, with very high long chain n-3 PUFA, do not represent the
n-3 PUFA intake of Americans, result in super physiological levels of membrane long
chain PUFA, and thus are limited in their translatability. While the feeding period of this
study was short, there were significant and meaningful differences in the lipid
composition of tissues, like RBCs, that are used to assess whole body PUFA metabolism
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in human studies. The lack of a PUFA effect on the cytokine response does not support a
role for PUFA in significantly affecting the acute inflammatory response.
Beyond cytokines, several other inflammation-related measures were investigated.
In a manner related to the RBC profile, the hepatic PL PUFA profile and eicosanoids
response to LPS was determined. According to the PL profile, LA was significantly
higher by the n-6 diet content and ALA by the n-3 PUFA content. EPA concentration in
PL in the liver was affected by both n-6 and n-3 PUFA levels in the diets. Higher dietary
n-3 PUFA and lower dietary n-6 PUFA could lead to higher EPA level in the PL in liver.
From posthoc analysis, LH group mice showed significantly higher EPA level than the
rest groups. The result implies that long-chain n-3 PUFA biosynthesis is affected by
competitive inhibition from n-6 PUFA (LA) which is same as we observed in the red
blood cell lipid profiling. In the TAG PUFA profile, similar result was also found that
AA biosynthesis may be affected by competitive inhibition from ALA in the diet.
In the oxylipin analysis, PGE2 was higher in the mice fed the HL diets, but the
effect was not significant after adjusting for multiple testing. PGE2 is an AA-derived
eicosanoid which has pro-inflammatory effects such as inducing production of IL-6 and
increasing vascular permeability (24, 25). PGE2 may be involved into the inflammatory
responses by stimulating NF-κB pathway (26). Although we did not see difference of AA
between the dietary groups in PL, there was difference in TAG AA level across the
groups. High AA in the TAG in liver is constant with the increased level of PGE2 level in
liver, even though the effect was not significant after multiple testing. Interestingly, some
studies have suggested that TAG may also be a source of lipids for oxylipin biosynthesis
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in inflammatory cells (27). In our study, AA in the TAG rather than in the PL may lead to
higher level of PGE2 in the HL group. The result may also suggest that a higher n-6 to n3 PUFA ratio in the diet may lead the fatty acids metabolic flux to form more n-6 PUFA
derived eicosanoids in liver.
In the hepatic gene expression data, we can see that most of NF-κB pathway
related genes especially Nfkb1 were enhanced by high dietary n-6 PUFAs. Ccl2 and Ccl3
genes play important roles in promotion of recruitment and migration of immune cells
such as neutrophil and macrophages to inflammation site (28, 29). Increased Ccl2 and
Ccl3 expression in high n-6 PUFA groups suggests dietary n-6 PUFA may promote
immune cell recruitment or migration during acute inflammation. Furthermore, IL-1β, IL6, and Tnf-α genes are downstream genes which are stimulated after NF-κB translocation
which implies high dietary n-6 PUFA may promote NF-κB translocation which initializes
NF-κB downstream (30).
PPAR-α pathway is associated to lipid oxidation which is inversely correlated
with inflammatory responses (31). From PPAR-α pathway, the results indicated that high
dietary n-6 PUFA led to higher expression of Acox-1, Cpt-2, Hmgb1, and Ppar-α which
indicates high dietary n-6 PUFA levels promote gene expression in the PPAR-α pathway.
The result is not consistent with our hypothesis, but one caveat is that these animals were
under LPS stress. Research indicated that dietary long-chain n-3 PUFAs could enhance
PPAR-α pathway with increased Acox1, Ppar-α expression in the mice (32, 33).
Scientists also found increased Cpt-2 gene expression in rabbits after treatment with high
n-3 PUFA diet (34). On the other hand, oral long-chain n-3 PUFA supplements have
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shown the effect of reducing the expression of Hmgb1. However, some papers indicated
that PUFAs (LA and ALA) could function as ligands for PPAR-α pathway (35, 36). Thus,
based on what we observed from our data, we believe that PPAR-α pathway is positively
related with overall PUFA level in the diets.
From the pathway of lipogenesis, we can see that high n-6 PUFA diets could lead
to increased expression of lipogenesis related genes including Acaca, Dgat2, Elovl5, Me1,
and Srebp-1. Expression of Fasn, which encodes the fatty acid synthetase to catalyze the
biosynthesis of palmitic acid from acetyl-CoA and malonyl-CoA, was significantly
increased in the HL group compared with LL which means dietary high n-6 to n-3 PUFA
ratio could enhance Fasn expression. Other studies showed that dietary n-3 PUFA could
reduce expression levels of lipogenesis related genes such as Acaca, Fasn, Scd-1, and
Srebp-1 in rodent liver (37-39). Furthermore, scientists also pointed out that DHA treated
C57BL mice had lower FAS and ME activity levels (40). However, some other studies
indicated that dietary PUFAs (both n-6 and n-3 PUFAs) could inhibit lipogenesis by
inhibiting lipogenic gene expression (41, 42). In this study, we found high n-6 PUFA
diets were positively related to lipogenesis in the mice. Moreover, high n-6 to n-3 PUFA
ratio may also lead to lipogenesis by increasing the gene expression level of Fasn.
From both PPAR-α and lipogenesis pathways, we know that higher overall
dietary PUFA would increase lipid oxidation. However, if n-6 and n-3 PUFAs are not
balanced, over-intake of n-6 PUFA would lead to more lipogenesis than lipid oxidation.
From lipid profiles in liver, there was no difference in total PL, TAG, and DG.
However, both CE and FFA were significantly affected by the content of n-6 in the diet.
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There was significantly more CE in the low n-6 diets, and the majority was due an
increase in myristic acid (14:0). The other prominent difference was with oleic acid
(18:1n9) which was also lower. Is the difference in hepatic CE due to specific fatty acids,
or due to an overall reduction across all fatty acids? When the fatty acid content is
expressed in percentage, the only notable difference is in oleic acid. Abbey et al. (43)
found that replacement of dietary SFAs with PUFAs could lower the total plasma
cholesterol and LDL cholesterol. Berry et al. compared efficiency of reducing LDL
cholesterol between dietary MUFAs and PUFAs. He found that PUFAs were more
effective on reducing LDL cholesterol than MUFAs (44). Our PUFA diets have same
amount of SFAs and total fats. HH and HL have higher PUFA contents but lower MUFA
contents compared to LH and LL diets. Thus, the reason that lower levels of CE in the
mice fed with HH and HL diets could be PUFA have better ability to reduce LDL
cholesterol. For the FFA, there was approximately double the amount in the low n-6 diets.
In terms of percentage, there is no clear effect across any specific fatty acid, indicating
that increased n-6 PUFA reduces the overall FFA content.
In summary, in our acute inflammation model, high n-6 PUFA diets appear to
promote acute inflammation caused by sublethal dose of LPS injection. However, the
effect is modest. As most of the suggested effects were lost with control of the FDR, it
may be that this study was underpowered to detect significant differences. To our
knowledge, this is the first study to investigate the effect of dietary PUFA on acute
inflammation using diets with PUFA formulas within physiological ranges consumed by
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Americans. The diets did cause the predicted changes in tissues of eicosanoid precursors,
and also recapitulated the well-known cholesterol lowering effect of n-6 PUFA.
High dietary n-6 PUFA led to higher food intake which consequentially caused
higher weight gain in the mice. We found that mice fed with HH diet had increased
weight gain because of increased fat and lean while the mice fed with HL diet only had
increased fat. The results suggest that high n-6 PUFA with low n-3 PUFA in the diet may
cause fat accumulation through enhanced lipogenesis. Cytokine analysis showed that
there were no differences of inflammatory cytokine concentration. The reason may be
moderate PUFA contents and ratios in our diets which could not affect the acute
inflammation in short feeding period. In the lipid profile of red blood cells, higher levels
of EPA and DHA were driven by high intake of n-3 PUFA. DHA level was also
enhanced under low n-6 PUFA diet which implies there is a competitive inhibition from
n-6 PUFA on DHA biosynthesis. In the liver lipid profiles, there was no difference in
overall fatty acid levels in major lipid classes, PL and TAG. In PL, LA and ALA were
significantly higher in the high n-6 PUFA dietary groups and high n-3 PUFA dietary
groups, respectively, due to their original higher concentration in the diets. Higher dietary
n-3 PUFA and lower dietary n-6 PUFA could lead to higher EPA level in the PL in liver
which also suggests EPA biosynthesis is affected by competitive inhibition like what we
observed in the red blood cells. In the TAG, increased AA was seen in the HL group
which suggests that AA biosynthesis is also affected by competitive inhibition from ALA
in the diet. Higher level of PGE2, AA-derived eicosanoid, was driven by high n-6 PUFA
and low n-3 PUFA in the diets. In our study, the source of PGE2 may be from TAG
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instead of PC due to higher AA level in the HL group in the TAG. Our oxylipin result
suggests that higher n-6 to n-3 PUFA ratio in the diet may lead fat metabolic flux to form
more AA-derived eicosanoids in the liver. From gene expression data, high dietary n-6
PUFA could promote expression level of lipogenesis and NF-κB related genes which are
positively related to inflammation. Higher overall PUFA content could stimulate PPAR-α
pathway which is associated to fat oxidation. Except the effect on inflammation, dietary
PUFA showed a better ability to reduce LDL cholesterol in the liver than dietary MUFAs.
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CHAPTER 3

CHRONIC INFLAMMATORY STRESS VIA LOW-DOSE

LIPOPOLYSACCHARIDE INFUSION

Introduction
Previously, we evaluated the effects of modifying dietary PUFA, within
physiologically relevant ranges, in an acute inflammation model by injection of sublethal
dose LPS into mice. Yet, metabolic inflammation, common in those consuming modern,
Western Diets, is thought to result from a low-grade inflammatory stress from LPS. In
this chapter, the implementation of a low-grade, chronic stress was explored via methods
to increase plasma LPS.
Interestingly, scientists have found that IAP, detoxifies luminal endotoxin
including LPS, and prevents gut-derived systemic inflammation (1). Some studies have
reported that the detoxification of LPS by IAP is also due to the dephosphorylation of the
lipid A moiety (2, 3). In addition, IAP is induced by LPS and then detoxifies LPS to
suppress excessive TLRs and TNF signaling (4). However, it has been reported that
dietary L-Phe inhibits endogenous IAP activity which is associated with an increase in
serum endotoxin levels by, presumably be inhibiting its dephosphorylation (3). There is
some indication that gut levels of IAP may be induced by dietary-derived compounds.
For example, a group reported indicated that Resolvin E1, a metabolite of EPA, induces
IAP expression in intestinal epithelial cells (5). Thus, a higher level of n-3 PUFA may
increase IAP expression which facilitates LPS detoxification.
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The goal for this experiment was to evaluate methods to cause chronic
inflammation in mice. This included testing whether L-Phe promotes inflammation,
presumably via inhibiting IAP activity. In addition, a low-grade inflammatory stress was
induced via osmotic mimipump installed in the mice and delivering LPS based on the
method of Cani et al (6). Hereby, we have two hypotheses in this study. First hypothesis
is stronger inflammatory responses would be observed in the mice installed with pump
with LPS compared to pump-control mice (saline in the pump). The second hypothesis is
that mice fed with L-Phe contained drinking water would show increased inflammatory
responses compare to control mice. The primary endpoint for inflammatory responses is
levels of cytokines. Other endpoints measurements included weight gain, glucose
tolerance, inflammation related gene expression levels.
Materials and Methods
Animals and diets
Forty male weanling mice (C57BL/6) were purchased from Jackson Laboratory
(Bar Harbor, ME, USA) and fed chow until all reached at least 20 g in weight. Mice were
allocated into one of four groups (10 mice each group) with balanced initial weight across
the groups. These were control, pump-control (mini osmotic pumps filled with saline),
pump-LPS group (mini osmotic pumps filled with 200 μL 1.7 μg/μL LPS solution), and
L-Phe group (10 mM L-Phe in drinking water) (1). Mice were fed the TWD for 6 weeks
(starting three days before pump implantation). Mice were housed individually. Mice
were weighed every four days and diet intake measured every other day. Body
composition of mice not fit with pumps was measured every two weeks.
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All mice were fed the TWD. The TWD contains 50.1% energy (kcal) from
carbohydrate, 34.5% energy from fat and 15.4% energy from protein. The n-6 to n-3
PUFA ratio is roughly 10:1 which represent the Americans’ average PUFA intake. The
components of TWD are summarized in the Table 3.1.

TABLE 3.1 Components of TWD.
Components of TWD
Casein
L-Csytine
Corn starch
Maltodextrin
Sucrose
Olive oil
Soybean oil
Corn oil
Lard
Beef tallow
Andydrous milkfat
Cholesterol
Cellulose
Mineral mix
Sodium Chloride
Vitamin mix
Choline bitartrate
TBHQ, antioxidant

g/kg
190.00
2.85
230.00
70.00
261.32
28.00
31.40
16.50
28.00
24.80
36.30
0.40
30.00
35.00
4.00
10.00
1.40
0.03

Chronic inflammatory challenge, mice sacrifice, and sample collection
Mice in the pump control and pump LPS groups were implanted subcutaneously
with an osmotic mini-pump (Alzet Model 2006; Alza, Palo Alto, CA). The pumps were
filled with either NaCl (0.9%) or LPS solution to infuse 300 μg•kg-1•day-1 for 6 weeks
(200 μL of 1.7 μg/μL LPS was loaded in the pump reservoir) in the mice. Before the
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surgery, all the surgical equipment and the working area were sanitized by Nolvasan
solution. Mice were anaesthetized by ketamine (supplied by Dr. Olsen in LARC). A
section of skin approximately 1 cm away from the tail was sanitized with betadine and a
small cut was made to open the skin with scissors. The minipump was inserted under the
skin, and a stapler was used to close the incision. Next, the area was cleaned again with
betadine. The mice were left on a heating blanket to maintain body temperature. Once
mice were able to move by themselves, they were returned to their cages.
Oral glucose tolerance test (OGTT)
The OGTT was conducted one week before sacrifice. Six mice from each
treatment group were randomly selected for OGTT. Mice were moved to clean cages
with a paper towel on the bottom instead of corn cob bedding, but the water bottle was
kept. The weight of each mouse (weight of minipump were included) was taken and used
to calculate the dose of glucose (2 g/kg body weight) needed. The mice were fasted for
six hours prior to the test.
Eight minutes before a mouse was tested, anesthetic cream was applied to the tip
of each mouse tail and allowed to take effect. Next, a mouse was placed on the
restraining device. The tail was cleaned with an ethanol soaked wipe. Using razor blade,
a cut was made at 0.5 mm from the end of the tail. Two microliters of blood was
collected from the tail with a pipette. After blood collection, the bleeding was stopped by
pressure applied with a clean tissue. Three glucose measurements were made with a
glucose meter and results at each time point was averaged from the three measurements.
Once fasting data had been collected, the mice were gavaged with the appropriate dose of
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glucose, based on body weight. After fifteen minutes, blood glucose was measured again
as described previously. Overall, glucose measurements were made at 15, 30, 60, 90, and
120 minutes.
After 6 weeks on the treatment, mice were sacrificed and tissues collected as
described in the Chapter 2.
Plasma cytokine analysis
The following cytokines, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12
(p70), IL-17, MCP-1, IFN-γ, TNF-α, MIP-1α, GM-CSF, and RANTES were measured in
plasma by using Q-PlexTM array (multiplex ELISA arrays) kit (Quansys Biosciences,
Logan, UT) according to manufacturer’s directions. The images were captured by
Quansys Q-viewerTM Imager.
Calibrator (standards) was dissolved into 500 μL sample diluents and then a series
of dilutions were made to prepare an eight-point standard curve with seven different
concentrations and one blank in a low-binding 96-well plate. Thirty microliters of prethawed plasma sample were mixed with 30 μL sample diluents in the same plate. Next,
50 μL of standards and sample mixtures were transferred to the Q-Plex array 96-well
plate. Sealed Q-Plex plate was placed on shaker for 1 hour at 500 rpm at room
temperature. After incubation, plate was washed with 200 μL of 1X working wash buffer
three times. Then, 50 μL detection mix was added into wells and the sealed plate was
placed back to shaker for another hour. The plate was washed three times again and then
50 μL Streptavidin-HRP 1X was added into each well. After 30 minutes incubation, plate
was washed six times. Fifty microliters of pre-mixed substrate A and substrate B was
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added into each well right after washing. Finally, Q-viewer imager was applied to capture
the image of the plate to calculate cytokine concentration.
Gene expression analysis
In this study, the genes we measured in the mice liver include 18s rRNA, Acaca,
Acox1, Ccl2, Ccl3, Cpt-2, CRP, Dgat-2, Elovl-5, Fasn, Hmgb-1, Ikb-α, IL-1α, IL-1β, IL6, ME-1, NF-κB-1, NF-κbib, Ppar-α, Ppar-β, Scd-1, Srebp-1, Tnf-α. The procedures of
measurements and data analysis were same as described in the Chapter 2.
Statistical analysis
Two hypotheses we have were analyzed by two samples t-test which was
performed with SPSS software version 19 (IBM Corporation, Armonk, New York, USA).
Data are reported as mean ± standard deviation.
Results
Food intake, body weight, and body fat composition
The food intake data is shown in Figure 3.1. There is no difference of food intake
between mice in the pump control group and pump LPS group. On the other hand, there
is also no difference between mice in the control group and L-Phe group. For the weight
gain, mice in the pump-LPS group gained significantly more weight than mice in the
pump control group (Fig. 3.2). The body fat percentage and fat gain between control and
L-Phe groups were not different (Fig. 3.3). Since it was not possible to assess body
composition on mice in the pump groups, adipose tissues were collected and weighed
after dissection. The weights of adipose tissue were not significantly different between
pump control and pump LPS group (Fig. 3.4).
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Oral glucose tolerance test
There were no differences in blood glucose level between pump control group and
pump LPS group at any time point. In addition, there were no differences in overall
glucose level (AUC) between these two groups. When we compared control group and LPhe group, there was also no difference for each time point and AUC (Table 3.2). After
normalizing the glucose level based on baseline (glucose level at 0 minute), there were
still no difference in AUC, but pump control group had significantly higher blood glucose
level at 120 minutes than pump LPS group (Table 3.3).
Plasma cytokine analysis
Cytokines analyzed in this experiment were IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-10, IL-12(p70), IL-17, MCP-1, IFN-γ, TNF-α, MIP-1α, GM-CSF, RANTES.
Most of the cytokines measured were under the detection limit. Only IL-1β, IL-3, IL-6,
and RANTES were consistently detected but there was no significant difference between
the pump control and pump LPS groups for these four cytokines. Furthermore, there was
also no difference between control and L-Phe groups (Table 3.4).
Tissue gene expression
Acaca, Acox1, Ccl2, Ccl3, Cpt-2, CRP, Dgat2, Elovl5, Fasn, Hmgb1, IL-1α,
IL-1β, IL-6, ME1, NF-κB1, Nf-κbib, Ppar-α, Ppar-d, Scd-1, Srebp-1, Tnf-α genes were
measured in this study. 18s rRNA was used to normalizing the genes across the samples.
Normalized genes in the control group were considered as control to calculate the fold
changes of each gene compared to other treatment groups. Fold changes are shown in the
Table 3.5. The results indicate that there were no significant differences in all
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inflammation related genes between pump control group and pump LPS group. Moreover,
there were no difference in genes between control group and L-Phe group.
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FIGURE 3.1 Total food intake of mice across different treatment groups. The data
represents mean ± SD. Means with different superscripts are significantly different
(p<0.05).
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FIGURE 3.2 Mice weight gain across the different treatment groups. The data
represents mean ± SD. Means with different superscripts are significantly different
(p<0.05).
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FIGURE 3.3 Mice body fat percentage between control group and L-Phe group. The
data represents mean ± SD.
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FIGURE 3.4 Weight of adipose tissues of mice in the pump control and pump LPS
groups. The data represents mean ± SD.
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TABLE 3.2 Blood glucose levels at each time point and overall blood glucose level in
OGTT across different dietary PUFA groups.

Time (min)

Pump control

Pump LPS

Control

L-Phe

0
15
30
60
90
120
AUC

124.5±33.2
235.3±55.0
243.4±62.7
201.9±27.5
177.8±31.0
160.4±47.1
23737.3±3815.5

137.7±16.5
280.6±54.0
247.5±38.2
213.9±28.0
145.8±22.0
125.1±16.3
23479.2±2425.1

134.5±15.7
247.5±39.7
244.8±39.8
185.6±40.5
152.1±29.6
146.1±45.3
22544.2±3182.9

120.7±33.4
240.8±31.6
251.4±48.5
220.4±84.8
167.4±33.6
170.5±49.0
24355.0±5298.9

The data represents mean ± SD.

TABLE 3.3 Normalized blood glucose levels at each time point and overall blood
glucose level in OGTT across different dietary PUFA groups.

Time (min)

Pump control

Pump LPS

Control

L-Phe

15
30
60
90
120
AUC

110.8±48.0
118.9±62.3
77.4±47.9
53.3±39.4
35.9±44.0a
8797.1±4389.3

142.9±59.6
109.8±50.6
76.2±36.7
8.1±32.2
-12.6±18.3b
6952.6±3728.6

113.0±39.9
110.3±51.7
51.1±48.1
17.6±36.3
11.6±51.1
6487.6±4145.5

120.1±31.7
130.7±42.7
99.7±85.0
46.7±25.4
49.8±43.4
9882.6±4812.0

The total glucose level in 120 minutes was normalized by glucose level at 0 minute. The
data represents mean ± SD. Means with different superscripts are significantly different
(p<0.05).
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TABLE 3.4 Plasma cytokine concentration across four dietary groups.

Cytokine concentration (pg/mL)

Pump control

Pump LPS

Control

L-Phe

IL-1β
IL-3
IL-6
RANTES

56.40±15.88
11.80±1.29
23.29±5.68
16.86±6.50

77.68±21.36
14.62±5.78
34.01±13.57
23.62±11.18

61.21±17.63
12.28±1.76
29.99±16.40
23.20±12.97

46.67±18.18
13.17±2.01
20.60±4.43
30.03±20.36

The data represents mean ± SD.

TABLE 3.5

Mice liver gene expression.

Genes (log2 fold change)

Pump control

Pump LPS

Control

L-Phe

1.29±0.88
1.31±0.89
1.34±0.97
1.35±1.03
1.29±0.90
1.57±1.26
1.27±0.80
1.22±0.75
1.30±0.88

2.40±2.08
3.36±3.38
1.51±2.01
1.50±1.51
0.99±0.79
0.66±0.54
2.08±2.36
1.72±1.87
2.44±2.13

1.41±1.07
1.26±0.78
1.30±0.87
1.73±1.96
1.43±1.12
1.35±0.95
1.27±0.82

2.62±3.63
1.97±2.69
1.58±1.36
2.67±2.67
1.89±2.42
2.06±2.11
1.98±2.20

1.28±0.81
1.29±0.89
1.32±0.94
1.25±0.75
1.25±0.74

1.69±2.05
1.86±2.53
1.85±2.45
1.95±2.72
2.33±2.92

NF-κB pathway
Ccl2
Ccl3
CRP
IL-1α
IL-1β
IL-6
Nfκb1
Nfκbib
Tnf-α

2.60±2.01
2.83±1.74
2.25±1.37
2.13±1.40
2.75±2.20
1.63±1.10
2.45±1.36
2.32±1.21
2.43±1.69

2.41±1.99
4.14±4.64
1.71±1.33
1.78±1.53
3.77±4.04
1.02±0.92
2.07±1.59
2.15±1.68
3.54±4.22

Acaca
Dgat2
Elovl5
Fasn
Me1
Scd-1
Srebp-1

2.21±0.94
2.22±2.35
1.93±0.84
1.54±1.02
1.92±1.29
2.00±1.41
1.50±0.58
2.88±4.46
1.15±0.42
1.40±1.41
2.97±1.98
2.98±2.31
1.74±0.90
1.62±0.99
PPAR-α pathway
1.93±1.13
1.70±1.27
1.67±0.88
1.42±1.03
2.23±1.29
1.77±1.37
1.85±1.06
1.41±0.95
2.53±1.45
1.91±1.34

Lipogenesis

Acox1
Cpt-2
Hmgb1
Ppar-α
Ppar-d

The data represents mean ± SD. Data with different superscripts are significantly
different (p<0.05). NS means not significantly different.
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Discussion
The focus of this experiment was to evaluate a chronic inflammatory stress model
and to determine if L-Phe had an effect on inflammation. In this study, there were two
control groups. One group did not receive a minipump and was fed the same diet as other
treatment. The other control group was pump-control group with saline in the pump
which evaluated the possible effect from minipump installed in the mice body. The TWD
was used in this experiment as it was used in the first experiment and third studies. Thus,
using TWD as a standard diet here will give us more accurate and reasonable evaluation
on later experiment which is studying the effect of typical American diets with different
n-3 and n-6 PUFA levels and ratios on inflammatory responses.
Our first hypothesis in this study is slowly released LPS via minipump would
increase the inflammatory responses in the mice.
The diet intake and weight gain data indicate that mice in the pump LPS group
had more weight gain than pump control group when their food intakes are roughly equal
which is expected in our hypothesis. However, the adipose tissue weights collected from
dissection were not significantly different. In a similar study done by Cani, mice
implanted with minipump filled with saline or LPS were studied. The mice in the pump
LPS group had higher weight gain compared with pump control group. Their result is
consistent with what we observed. In Cani’s study, slowly released LPS from osmotic
minipump was designed to mimic the metabolic endotoxemia obtained from high fat diet
feeding (72% fat). They suggested that bacterially related factor like LPS is responsible
for high-fat diet induced obesity via binding to CD14 (6).
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In OGTT, since the blood glucose levels at 0 minute (baseline) were different
across the dietary groups, normalized blood glucose levels should be used to calculate
AUC. The results indicate that mice in the pump control group had higher blood glucose
concentration at 120 minutes, but not the other time points and AUC. The results show
that slowly released LPS did not lead to insulin resistance and glucose intolerance. The
result is also comparable to Cani’s study (6). Scientists reported that TLR4 was involved
into insulin resistance caused by LPS (7). To continuously study the mechanism,
understanding the regulation of TLR4 could be important.
Plasma cytokine level is primary endpoint to measure the inflammatory responses.
In this experiment, there were only four cytokines present at high enough levels to be
reliably detected. Compared with the cytokine levels in the acute inflammation study,
overall low concentration of cytokines could imply weak inflammatory responses in the
mice. The possible reason for the weak inflammation could be slowly released LPS
would only cause weak inflammation. Another possible reason for low cytokine levels is
not enough LPS from minipump releases to tissue and blood. In Cani’s study, they
indwelled an intrafemoral catheter into the femoral vein in the mice which may improve
infiltration of LPS into blood (6, 8).
In terms of hepatic gene expression, although mice in the pump LPS group have
relatively higher inflammation related gene expression levels, there is no difference
between pump control and pump LPS groups which suggests that over expressions of
these genes are caused by minipump implantation instead of slowly released LPS.
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Our second hypothesis is that supplement of L-Phe in the drinking water could
enhance inflammatory responses. Although previous studies have suggested that L-Phe
may deactivate IAP which would inhibits absorption of endotoxin (1, 3), our results
showed that there were no significant difference between control group and L-Phe group
on weight gain and dietary intake, blood glucose concentration, cytokine levels, and
inflammation related gene expression levels. It is possible that the diets were not
sufficiently high in fat to promote endotoxin absorption, or perhaps there is another
explanation. Further study on in vivo IAP activity and IAP coded gene expression could
be helpful to investigate the mechanism of inhibition from L-Phe on IAP. Nevertheless,
inclusion of L-Phe in the drinking water does not appear to promote metabolic
dysregulation.
In summary, the chronic inflammation model we tested could only cause modest
inflammatory responses in vivo. More weight gain in pump-LPS group suggests possible
chronic inflammation via CD14-dependent mechanism. Overall, this model could be a
useful model for inducing chronic inflammation for further studying the effects of our
PUFA diets on chronic inflammatory responses. For the other goal we want to test in this
experiment, L-Phe could not cause inflammation in mice through inhibition of IAP. To
induce chronic inflammation by L-Phe, a longer period of feeding or higher concentration
of L-Phe supplements in the drinking water may be necessary. Measurements of IAP
activity and expression levels of IAP related genes would help us understand more
mechanism of IAP inhibition from L-Phe.
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CHAPTER 4

EFFECT OF MODIFYING DIETARY N-6 AND N-3 PUFA ON METABOLISM

AND INFLAMMATION IN CHRONIC INFLAMMATION MOUSE MODEL

Introduction
In Chapter 2, the rationale was given for using TWD modified PUFA diets in our
experiments to study the effect of dietary PUFA on inflammation. As the high fat diet fed
to mice in a previous study in the Ward Lab did not induce chronic inflammation, an
alternate model was tested. Although the results indicated that implantation of an osmotic
mini-pump with LPS induced a weak inflammatory response in the mice (increased
weight gain), yet, by that time this study had already been conducted. Thus, this chapter
describes a study to evaluate the role of the n-6 to n-3 ratio and total PUFA content on the
inflammatory response in mice subjected to a chronic stress. The same TWD-based n-6
and n-3 diets were used as in Chapter 2.
Low-grade, chronic LPS administration may not lead to an increase in systemic
cytokine levels due to endotoxin tolerance which is a defense mechanism of the immune
system (1). Fischer applied osmotic minipumps in the mice for chronic LPS infusion and
their results indicated that there was no weight gain (2) or fat mass changes (3). However,
chronic exposure to LPS caused hyperglycemia and insulin resistance (3). Effects of lowgrade LPS on inflammation related signaling pathways were reported. Ma et al. found
that low dose LPS infusion in the rat brain activated transcription factors such as NF-κB
and cyclic AMP responses element which are regulated by mitogen-activated protein
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kinases (MAPKs) and IκB-α (4). Trifilieff et al found that PPAR-α showed antiinflammatory activity by interfering Th2 pathways in chronic inflammation induced by
LPS in the mice lung (5). It has also been shown that chronic inflammation induced by a
low-grade dose of LPS results in similar metabolic effects of a high fat diet, which
promotes weight gain by increasing the concentration of phosphorylated NF-κB and IKK
(3). Based on results from these studies, LPS infusion enhances NF-κB and lipogenesis
pathways and suppressed the PPAR-α pathway. Thus, we hypothesized, high dietary n-6
PUFA will promote an inflammatory response and will be accompanied with increased
NF-κB pathway activation and lipogenesis. Conversely, high dietary n-3 PUFA will
suppress the NF-κB pathway and lipogenesis while increasing PPAR-α pathway.
The goal of this experiment was to evaluate the effect of n-6 to n-3 PUFA ratio
and their concentration on chronic inflammation. The diets used in this study were the
same TWD-based PUFA diets used in Chapter 2. The NF-κB pathway, PPARs pathway,
and lipogenesis are known to be affected by the inflammatory stress of low-grade LPS
infusion, and are hypothesized to be differentially affected as a function of dietary PUFA.
Materials and Methods
Animals and diets
Forty weanling male C57BL/6 mice (Jackson Labs, Bar Harbor, ME, USA) were
randomly separated into four groups with balanced initial weight across the groups. Mice
were housed individually and fed with the same HH, HL, LH, and LL PUFA diets for 6
weeks. Mice were weighed every four days and diet intake was measured every other
day.
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Chronic inflammatory challenge, mice sacrifice, and sample collection
Mice with body weight over 20 g were implanted subcutaneously with an osmotic
mini-pump filled with LPS solution. The implantation procedures and pump parameters
were the same as described in the Chapter 3, as was the sacrifice and tissue collection.
Oral glucose tolerance test
The OGTT was conducted one week before sacrifice. Six mice from each
treatment group were randomly selected for OGTT. The procedures of OGTT were
described in the Chapter 3.
Plasma and adipose cytokines analysis
The concentration of cytokines, which includes IL-1α, IL-1β, IL-2, IL-3, IL-4, IL5, IL-6, IL-10, IL-12 (p70), IL-17, MCP-1, IFN-γ, TNF-α, MIP-1α, GM-CSF, RANTES,
in the plasma were measured by using Q-PlexTM array as described in the Chapter 3.
Fatty acid profile
The fatty acid profile of red blood cells and livers was determined using
procedures described in Chapter 2.
Fatty acids oxygenated compounds analysis
Fatty acids oxygenated compounds in the mice liver were analyzed by LCMS/MS. Extraction method and analytical procedures are described in the Chapter 2.
Gene expression analysis
Genes measured in liver and adipose tissue include 18s rRNA, Acaca, Acox1,
Ccl2, Ccl3, Cpt-2, CRP, Dgat-2, Elovl-5, Fasn, Hmgb-1, Ikb-α, IL-1α, IL-1β, IL-6, ME-
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1, NF-κB-1, NF-κbib, Ppar-α, Ppar-β, Scd-1, Srebp-1, and Tnf-α. The procedures are
described in the Chapter 2.
Statistical analysis
A 2x2 factorial design was applied to evaluate the main effects of n-6 PUFAs and
n-3 PUFAs with the interaction effect based on n-6 to n-3 PUFA ratio on inflammatory
responses. Shapiro-Wilk test was used to test the normality of data and a log
transformation was applied if the original data was not normal distributed. A FDR was
used and controlled at 0.05, which reduces the risk of false positives, by adjusting pvalues of analysis due to multiple comparisons. Analyses were performed with SPSS
software version 19 (IBM Corporation, Armonk, New York, USA) and SAS 9.4 (SAS
Institute Inc., Cary, NC, USA). Data was reported as mean ± standard deviation.
Results
Food intake, body weight and feed efficiency
In this experiment, there was significantly higher food intake in mice fed the low
n-6 PUFA diets (LH and LL) (Fig. 4.1). There was no difference across the dietary
groups for weight gain (Fig. 4.2). It was not possible to assess body composition by MRI
due to the minipumps. Feed efficiency was calculated as the ratio of weight gain to food
intake (Fig. 4.3). This parameter allows for the normalization of growth to food intake.
According to the data, there was an n-6 PUFA diets effect for higher feed efficiency.
Oral glucose tolerance test
For the OGTT, blood glucose levels are shown as a function of time and
treatments in Table 1. At baseline, mice fed with high n-6 PUFA diets had significantly
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lower blood glucose than those fed with low n-6 PUFA diets. However, at 60 minutes,
mice in the high n-6 group had higher blood glucose. Integrating all the data to produce
an area under the curve (AUC), mice in the HH group had a tendency to have a higher
overall blood glucose than the mice fed with LH diet (α=0.091), according to a post-hoc
analysis. There was an interaction effect at both 30 and 60 minutes for mice fed the high
n-6 diets, in that the levels were higher in the HH group, compared to the HL group at
both time points.
As noted from data, mice fed the low n-6 diets had a significantly higher baseline
glucose level. To assess how glucose was metabolized and account for the high baseline
level, a second analysis was preformed on the data after normalization to baseline values.
Table 4.2 showed blood glucose levels at each time point and overall blood glucose level.
As we can see from the data, from 30 minute to 120 minute, mice fed with high n-6
PUFA diets had significantly higher blood glucose levels than those fed with low n-6
PUFA diets. Furthermore, mice in the high n-6 PUFA groups also showed higher overall
blood glucose level compared with the other groups.
Fatty acid profile of red blood cells
The percentage of red blood cell PUFAs are listed in the Table 4.3. The three
dominant PUFAs were LA, AA, and DHA. According to the statistical analysis, after
adjustment for multiple comparisons, there were several differences. For example, there
was more LA and eicosadienoic acid (C20:2 n6) in the mice fed with high n-6 PUFA
diets. Surprisingly, there was more DGLA (C20:3 n6) in the mice with low n-6 PUFA
diets, which we also found in Chapter 2. There were no differences in the AA level
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between groups. On the other hand, there was more ALA and EPA in the mice fed with
high n-3 PUFA diets. Higher levels of DPA (C22:5 n3) and DHA have been shown in the
LH group. N-3 index in the mice red blood cells indicated that n-3 long-chain PUFA
levels were affected by both PUFA content (high n-3 PUFA level) and ratio (lower n-6 to
n-3 PUFA ratio).
Plasma cytokine analysis
The following cytokines were analyzed in plasma; IL-1α, IL-1β, IL-3, IL-5, IL-6,
IL-10, IL-12, IL-17, IFN-γ, MCP-1, MIP-1α, GM-GSF, KC, TNF-α, and RANTES.
However, most of the analytes were below the detection limit, and only two cytokines
(MCP-1 and RANTES) at a high enough concentration to be quantified. A log
transformation was applied to the data as the cytokine levels were not normally
distributed. The statistical analysis indicated that there was no significant difference
(Table 4.4).
Hepatic phospholipids profile
The lipid composition of the liver tissue was measured to investigate the effects of
the PUFA intakes, and to determine if there is a relationship with gene expression and
oxylipin production. The major focus was on PL profile (Table 4.5), as these molecules
provide the substrates for oxylipin synthesis and possibly gene expression.
In the PL PUFA profile of the liver, there were higher levels of LA and
eicosadienoic acid (C20:2 n6) in mice fed with high n-6 PUFA diets while a higher
DGLA level was observed in the mice with low n-6 PUFA diets. On the other hand, there
were lower levels of AA in the liver of mice with high n-3 PUFA diets. Moreover, there
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was higher ALA and DPA in the mice with high n-3 PUFA diets. In addition, higher EPA
and DHA levels in the liver were observed in the dietary high n-3 PUFA and low n-6
PUFA groups. EPA level was also affected by n-6 to n-3 PUFA ratio which higher ratio
leads to lower EPA level in the PL. The levels of long chain n-6 and n-3 PUFAs which
affected by dietary PUFAs could consequently affect the eicosanoids concentration in the
liver.
Analysis of oxygenated compounds of fatty acids
Data for the hepatic oxylipins is shown in Table 4.6. The concentration was
normalized by external standard. Although there were some differences in the hepatic
long chain PUFA precursors, there were no differences in oxylipins according to the 2way ANOVA, after correction for multiple comparisons.
Tissue gene expression
Genes normalized to 18s rRNA in the LH group were set to control and log2 fold
changes of each gene in the other dietary groups were compared. The results of hepatic
gene expression are shown in the Table 4.7. From Table 4.7, although there are some
differences in gene expression from 2-way ANOVA, there was no difference shown after
correction for multiple comparisons based on different inflammation related pathways.
Hepatic cholesterol esters
Although not a primary endpoint in the study, the contents of five hepatic lipid
classes in the liver were measured, and the data is shown in the Table 4.8. There is a
clearly lower CE level in the liver in mice fed the high n-6 PUFA diets. In fact, mice fed
the low n-6 diets had approximately 40% more hepatic CE than mice fed the high n-6
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diets. This result is consistent with the results from Chapter 2 where the diets had the
same effect on the CE fraction in the liver.
To better understand this effect, the fatty acid profile of CE was determined and it
is shown in the Table 4.9. Similar to the results in Chapter 2, there are several fatty acids
that appear to be affected by the n-6 content of the diet. However, it appears that oleic
acid (18:1n9) is the principal fatty acid that is significantly higher in the low n-6 diets that
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TABLE 4.1 Blood glucose levels at each time point and overall blood glucose level in
OGTT across different dietary PUFA groups.

Time
(min)
0
15
30
60
90
120
AUC

HH

HL

LH

LL

96.3±11.5
245.1±44.1
262.9±39.0a
213.3±52.5a
152.7±39.6
141.1±24.3
23411.5
±3111.9

106.3±18.2
250.3±35.1
228.0±38.2
175.9±32.0
144.7±25.1
126.6±14.9
21199.0
±2195.9

137.9±14.7
254.0±33.1
200.9±39.1b
147.4±24.8b
135.2±10.7
112.1±14.2
19523.5
±2225.1

152.8±23.3
276.8±42.9
234.6±27.4
175.7±29.1
140.9±25.2
126.0±16.3
21961.8
±2549.9

p-value for 2*2 ANOVA
Intera
n-6
n-3
ction
<0.01
NS
NS
NS
NS
NS
NS
NS
0.03
0.04
NS
0.05
NS
NS
NS
NS
NS
NS
NS

NS

0.04

The data represents mean ± SD. Means with different superscripts are significantly
different (p<0.05). NS means not significantly different.

TABLE 4.2 Normalized blood glucose levels at each time point and overall blood
glucose level in OGTT across different dietary PUFA groups.

Time
(min)

HH

HL

LH

LL

15
30
60
90
120
AUC

148.9±39.5
166.6±31.8
117.1±52.0
56.4±43.0
44.9±23.5
11858.3±2868.3

144.0±27.8
121.6±48.3
69.6±37.9
38.3±35.4
20.3±25.4
8439.0±3250.0

116.1±32.2
62.9±38.7
9.5±17.3
-2.7±7.6
-25.9±7.4
2971.4±1720.5

124.0±25.8
81.8±30.8
22.9±15.2
-11.9±30.1
-26.8±19.5
3628.4±1840.6

p-value for 2*2
ANOVA
Intera
n-6
n-3
ction
NS
NS
NS
<0.01 NS
NS
<0.01 NS
NS
<0.01 NS
NS
<0.01 NS
NS
<0.01 NS
NS

The total glucose level in 120 minutes was normalized by glucose level at 0 minute. NS
means not significantly different.
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TABLE 4.3

Fatty acid composition of red blood cells from four PUFA diets.

Diets
PUFA

HH

HL

Adjusted p value (FDR)
LH

LL

n-6

n-3

Interaction

Omega-6
C18:2 n6
(LA)
C20:2 n6
(Eicosadie
noic acid)
C20:3 n6
(DGLA)
C20:4 n6
(AA)

13.67±0.74

11.67±0.72

9.89±1.49

9.58±1.25

0.01

NS

NS

0.25±0.01

0.28±0.03

0.22±0.03

0.20±0.05

0.05

NS

NS

1.21±0.09

1.25±0.17

1.56±0.18

1.45±0.20

0.02

NS

NS

15.47±1.39

17.69±2.16

15.90±0.58

18.16±2.17

NS

NS

NS

Omega-3
C18:3 n3
(ALA)
C20:5 n3
(EPA)
C22:5 n3
(DPA)
C22:6 n3
(DHA)
n-3 index

0.34±0.08

0.11±0.04

0.22±0.01

0.10±0.03

NS

0.03

NS

0.24±0.02

0.10±0.02

0.69±0.08

0.18±0.04

NS

<0.01

NS

0.63±0.05

0.36±0.06

0.96±0.13

0.43±0.08

0.02

<0.01

NS

5.49±0.51

4.35±0.53

7.78±0.17

5.24±0.67

0.05

0.03

NS

5.73±0.51b

4.45±0.55b

8.48±0.24a

5.42±0.71b

<0.01

<0.01

<0.01

N-3 index is the sum of EPA and DHA. The data represents mean (percentage) ± SD.
Means of n-3 index with different superscripts are significantly different (p<0.05). NS
means not significantly different.

TABLE 4.4
groups.

Log(10) transformed plasma cytokine concentration across four dietary

Log10
concentration
(pg/mL)
MCP-1
RANTES

HH

HL

LH

LL

3.32±3.08
10.48±7.04

2.79±2.44
9.50±7.74

3.56±2.44
11.43±6.69

2.72±1.80
10.03±6.38

Adjusted p value (FDR)
Interact
n-6
n-3
ion
NS
NS
NS
NS
NS
NS

The data represents mean ± SD. NS means not significantly different.
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TABLE 4.5

PL PUFA composition in liver.
Diets

PUFA
(mg/g)
C18:2 n6
(LA)
C18:3 n6
(GLA)
C20:2 n6
(Eicosadien
oic acid)
C20:3 n6
(DGLA)
C20:4 n6
(AA)
C18:3 n3
(ALA)
C20:5 n3
(EPA)
C22:5 n3
(DPA)
C22:6 n3
(DHA)

Adjusted p value (FDR)

HH

HL

LH

LL

n-6

n-3

Interaction

9.40±0.84

7.50±2.00

7.05±0.33

7.18±1.05

0.03

NS

NS

0.12±0.01

0.18±0.12

0.08±0.03

0.15±0.03

NS

NS

NS

0.20±0.03

0.19±0.03

0.15±0.04

0.14±0.03

<0.01

NS

NS

1.00±0.05

0.83±0.26

1.21±0.15

1.15±0.22

<0.01

NS

NS

11.49±1.46

12.09±2.66

9.11±1.02

13.52±1.01

NS

<0.01

NS

0.10±0.03

0.03±0.01

0.08±0.03

0.03±0.01

NS

<0.01

NS

0.18±0.02b

0.04±0.02b

0.44±0.06a

0.13±0.04b

<0.01

<0.01

<0.01

0.25±0.02

0.14±0.03

0.24±0.03

0.17±0.03

NS

<0.01

NS

5.77±0.96

3.93±0.56

5.97±0.92

5.81±0.53

0.01

0.01

NS

The data represents mean ± SD. Data with different superscripts are significantly
different (p<0.05). NS means not significantly different.
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TABLE 4.6

Oxylipins in the liver.

Diets
Oxylipin
(ρmol/g)
15-HETE
12-HETE
5-HETE
4-OH DHA
14-OH DHA
17-OH DHA
PGE2
PGF2α
TXB2

Adjusted p value (FDR)

HH

HL

LH

LL

n-6

n-3

Interaction

0.22±0.28
0.94±0.74
0.07±0.08
0.06±0.05
0.16±0.15
0.06±0.05
0.03±0.01
0.09±0.06
0.08±0.09

0.21±0.14
1.77±1.58
0.09±0.04
0.05±0.04
0.19±0.17
0.06±0.03
0.03±0.02
0.09±0.06
0.11±0.09

0.13±0.09
3.91±4.24
0.06±0.08
0.05±0.08
0.44±0.26
0.04±0.02
0.05±0.04
0.14±0.17
0.29±0.43

0.20±0.13
0.67±0.34
0.11±0.06
0.04±0.03
0.08±0.05
0.05±0.03
0.06±0.00
0.05±0.03
0.04±0.03

NS
NS
NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS

Abbreviation: 15-hydroxyeicosatetraenoic acid (15-HETE), 12-hydroxyeicosatetraenoic
acid (12-HETE), 5-hydroxyeicosatetraenoic acid (5-HETE), 4-hydroxy-docosahexaenoic
acid (4-OH DHA), 7-hydroxy-docosahexaenoic acid (7-OH DHA), 14-hydroxydocosahexaenoic acid (14-OH DHA), 17-hydroxy-docosahexaenoic acid (17-OH DHA),
11-hydroxy-docosahexaenoic acid (11-OH DHA), prostaglandin E2 (PGE2),
prostaglandin F2α (PGF2α), thromboxane B2 (TXB2). The data represents mean ± SD.
Data with different superscripts are significantly different (p<0.05). NS means not
significantly different.
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TABLE 4.7

Hepatic gene expression.

Diets
Genes (log2
fold change)

HH

HL

Ccl2
Ccl3
CRP
IL-1α
IL-1β
IL-6
Nfκb1
Nfκbib
Tnf-α

2.02±1.44
1.46±0.81
2.24±1.24
1.47±0.76
2.31±1.25
1.96±2.12
1.94±0.80
2.07±0.95
1.77±1.15

1.71±1.23
1.36±0.89
1.84±1.46
1.61±1.30
2.06±1.52
2.58±2.09
1.98±1.27
1.97±1.31
1.68±1.46

Acaca
Dgat2
Elovl5
Fasn
Me1
Scd-1
Srebp-1

2.84±1.49
2.46±0.96
3.09±1.64
5.07±3.11
4.65±2.26
2.86±1.13
2.65±1.17

Acox1
Cpt-2
Hmgb1
Ppar-α
Ppar-d

3.23±1.28
2.47±1.17
1.06±0.46
2.58±1.10
2.20±1.22

LH

NF-κB pathway
1.91±2.64
1.60±1.76
1.24±1.03
1.15±0.78
1.22±0.88
1.43±1.41
1.26±1.07
1.30±1.19
1.51±1.56
Lipogenesis
2.15±1.47
1.24±1.04
2.53±1.40
1.17±0.80
2.53±1.83
1.41±1.51
2.41±1.39
1.32±1.21
2.57±1.78
1.13±0.66
2.27±1.53
1.19±0.85
2.18±1.33
1.22±0.93
PPAR-α pathway
2.03±1.48
1.11±0.58
2.30±1.62
1.16±0.78
2.17±1.49
1.33±1.26
2.14±1.79
1.10±0.51
2.41±1.13
1.23±0.99

LL

Adjusted p value (FDR)
Intera
n-6
n-3
ction

0.56±0.71
1.01±1.23
1.66±0.68
1.11±1.29
1.42±1.79
1.22±0.98
1.34±1.08
2.19±1.14
1.56±2.35

NS
NS
NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS

2.11±2.67
2.37±1.67
1.98±1.55
2.31±4.27
1.97±2.02
2.70±2.00
1.95±1.31

NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS

3.19±1.74
2.11±1.06
1.03±0.87
2.61±1.83
1.92±1.07

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

The data represents mean ± SD. NS means not significantly different.
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TABLE 4.8

Total liver lipid compositions from all lipid classes.

Diets
Fatty
acid
(mg/g)
PC
TAG
DG
FFA
CE
Total

p values for 2*2 ANOVA

HH

HL

LH

LL

n6

n3

Interaction

59.38±5.71
15.04±5.77
1.62±0.54
1.04±0.44
18.86±7.34
95.94±9.54

56.09±4.80
20.16±7.26
1.49±0.23
0.76±0.21
19.52±1.35
98.02±8.21

56.38±3.24
15.79±9.00
1.67±0.70
1.04±0.62
26.87±8.29
101.75±17.06

63.98±3.32
14.01±10.35
1.68±0.54
1.26±0.51
28.22±6.44
109.14±10.06

NS
NS
NS
NS
<0.01
NS

NS
NS
NS
NS
NS
NS

0.01
NS
NS
NS
NS
NS

The data represents mean ± SD. NS means not significantly different.

TABLE 4.9

Fatty acid content of CE in the liver.

Diets
PUFA
C14:0
(Myristic acid)
C14:1 n5
(Myristoleic
acid)
C16:0 (Palmitic
acid)
C16:1 n7
(Palmitoleic
acid)
C18:0 (Stearic
acid)
C18:1 n9 (Oleic
acid)
C18:2 n6 (LA)
C18:3 n3
(ALA)
C20:3 n6
(DGLA)
C20:4 n6 (AA)

p values for 2*2 ANOVA

HH

HL

LH

LL

n-6

n-3

Interaction

8.31±6.98

7.31±3.62

11.48±7.00

10.86±7.02

NS

NS

NS

0.64±0.60

0.58±0.24

0.86±0.44

0.80±0.43

NS

NS

NS

1.86±0.57

2.52±1.63

2.62±1.22

2.75±1.01

NS

NS

NS

0.34±0.07

0.46±0.14

0.64±0.39

0.71±0.51

NS

NS

NS

1.19±1.11

1.76±1.94

1.18±0.58

1.89±1.18

NS

NS

NS

2.16±0.66

2.84±1.03

4.91±2.44

6.21±4.68

0.02

NS

NS

0.70±0.18

0.73±0.21

0.59±0.18

0.64±0.41

NS

NS

NS

0.11±0.03

0.09±0.02

0.16±0.03

0.13±0.04

0.01

NS

NS

0.12±0.07

0.13±0.07

0.19±0.08

0.25±0.08

<0.01

NS

NS

0.19±0.07

0.27±0.07

0.15±0.04

0.27±0.12

NS

0.01

NS

The data represents mean ± SD. NS means not significantly different.
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Discussion
In this experiment, our goal was to investigate if the TWD-based PUFA diets with
different n-6 to n-3 PUFA ratios would have effects on chronic inflammation caused by
low-grade LPS stress. From the previous study, we examined feasibility and mechanism
of causing chronic inflammation through osmotic minipump release of LPS. The test
study of the minipump delivery system indicated higher weight gain in the pump-LPS
group mice than in the pump-control group, which shows the LPS effects on metabolism.
Thus, the mini-pumps LPS delivery system was used in mice with different PUFA diets
to investigate the effects on chronic inflammation.
Interestingly, mice fed with low n-6 PUFA diets consumed more food, yet there
was no difference in weight gain. This was due to the fact that these mice had a lower
feed efficiency. Previous work is in agreement, and has shown that n-6 PUFA enriched
diet increase feed efficiency in rodents. However, they used diet with 46.99% LA and
0.95% ALA from fat (28.8% fat in the diet) which is not within the physiological range
of human diets (6). Our result supported that n-6 PUFA enriched diet under physiological
range of intake could still increase feed efficiency. Although there are some other studies
showed that only dietary n-3 PUFA increased feed efficiency (7), our result suggested
that higher n-6 PUFA level is the factor that increased feed efficiency. Interestingly, this
finding is consistent with the results in the acute inflammation study (Chapter 2).
Furthermore, minimum level of n-3 PUFAs in the diet may also be critical for animal
growth. Scientists found that approximate 1% n-3 PUFA in the dry diet is necessary for
animal growth (8, 9). On the other hand, we found the average daily food intake in the
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chronic inflammation experiment (2.84 g per day) is significantly higher than the food
intake in acute inflammation model (2.41 g per day) (p value is 0.05). The result suggests
that the mice implanted with mini-pump may consume extra energy compared with
healthy mice.
In the OGTT, since the baseline glucose levels at 0 minute (baseline) were
different, a normalized value should be used to calculate the AUC. By normalizing
baseline glucose, we could also see how effectively the mice can handle the incoming
glucose load. According to the normalized data, mice fed high n-6 diets had higher
glucose levels after 30 minute and a higher AUC than the mice fed low n-6 diets. Thus, at
ranges of intake that are physiologically relevant to the US population, n-6 hinders
glucose tolerance under chronic LPS stress. Many studies have shown that high dietary n6 PUFA or a high n-6:n-3 ratio promotes insulin resistance and glucose intolerance while
a high n-3 intake reduces these responses (10-15). Our results indicated that the ratio may
not affect glucose tolerance since HH and LL diets have similar ratios. This result is also
supported by some research articles which they found dietary PUFA ratio did not
influence insulin sensitivity (16, 17).
The fatty acid composition in the red blood cells is a good indicator of dietary
fatty acid intake (18). According to the RBC profile, LA and ALA are directly linked to
the contents in the diets. Intermediates from PUFA elongation were also affected by
PUFA contents in the diets, yet they are not thought to participate in cell signaling
processes, like longer chain PUFA. EPA, one of the major precursors of n-3 PUFA
derived eicosanoid, was positively associated to dietary n-3 PUFA level. Moreover, we
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found LH group had highest EPA level which suggests possible competitive inhibition
from LA would decrease EPA elongation. DHA, which is the end product of n-3 PUFA
elongation, was higher in the LH vs. HH group, which suggests that there is competitive
inhibition for its biosynthesis from ALA. Research has shown that LA inhibits the
biosynthesis of n-3 long chain PUFAs via competing the rate-limiting enzymes of long
chain PUFA synthesis such as Δ5 and Δ6 desaturase (19-22). DHA is the major driver of
the n-3 index, and a value for mice in the LH diet (> 8% of RBC fatty acids) reached a
level associated with cardio protection in humans (23).
As the primary endpoints for inflammatory responses, the concentration of
cytokines in plasma samples appear to be low compared to the cytokine levels in the
acute inflammation study and most were below the detection limit. From cytokine
analysis, there is no difference of detected cytokines (MCP-1 and RANTES) across the
dietary groups. Cytokines are important biomarkers of inflammatory responses. Low
level of cytokine represents low inflammatory response. In this chronic inflammation
model, we found much lower cytokine levels than our acute inflammation model which
implies that slowly released LPS from mini-pumps did not cause strong inflammatory
responses. The possible reason for weak inflammatory responses could be not enough
amounts of LPS released by mini-pumps get into the mice circulation system to cause
inflammatory responses. Also, this can be caused by endotoxin tolerance mechanism in
the immune cells. This result is similar as we observed in the Chapter 3 which means the
pro- or anti-inflammation effects from our dietary PUFAs may not be so effective to
cause strong inflammatory responses in short feeding period.
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Since we did not see differences from cytokines between the dietary groups, other
measurements related to inflammation were investigated. The PUFA profile of PL
indicated levels of LA and ALA were driven by the PUFA contents in the diet. Lower
AA in the high n-3 PUFA groups shows competitive inhibition from ALA. Long-chain n3 PUFAs (EPA and DHA) were directly related to dietary n-3 PUFA content and were
competitively inhibited by dietary high n-6 PUFA.
Although we saw higher AA in hepatic PL in the low n-3 PUFA diet groups, there
was no difference of AA derived eicosanoids. In addition, there was no difference in long
chain n-3 derived oxylipins between groups even though EPA and DHA were
significantly higher in the LH and HH groups. Furthermore, the concentrations of
eicosanoids in the liver were very low compared with our acute inflammation study. As
we all know, eicosanoids are important inflammation mediators (24). Low levels of
eicosanoids suggest the inflammatory responses are weak in this chronic inflammation
model. Result from oxylipin analysis is consistent with cytokine data.
In liver inflammatory gene expression data, after controlling for FDR, we found
no difference for any genes related to the NF-κB, PPAR-α, or lipogenesis pathways
between the groups. These results are consistent with the cytokine and oxylipin data and
indicate the diets did not differentially affect the inflammatory response.
The only lipid class in the liver to be affected by the diets was CE, and this result
is consistent with the acute inflammation study. CEs were lower in the mice fed with high
n-6 PUFA diets. Previous studies in humans have consistently shown that higher overall
dietary PUFA levels reduce plasma cholesterol (25). While this measure was not a

118
primary objective of this study, it does show that changing the fat composition of the
typical US diet, within physiological ranges, does have an effect consistent with human
diets.
In summary, changing the PUFA content of the typical Western Diet, within
physiologic ranges actually consumed by Americans, did result in changes in tissue
composition of substrates for inflammatory signaling (AA, EPA and DHA). Yet, the
infused LPS only caused a modest inflammatory response in the mice as measured by
cytokines and eicosanoids, and there were no significant differences between treatments.
The reason could be (1) slowly released LPS from minipump may not fully get into mice
circulation system; (2) PUFA contents and ratios in our diets were not extreme; (3)
relatively short feeding period.
Despite the lack of an effect on inflammation, changing the PUFA content of the
diet did have significant and interesting effects on other aspects of metabolism. For
example, PUFA intakes affected feed efficiency. In addition, PUFA intakes affected
glucose metabolism, as measured by fasting glucose and also reduced insulin sensitivity.
Lastly, higher n-6 levels in the diet were associated with a significant decrease in hepatic
cholesterol esters.
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CHAPTER 5

CONCLUSION

In the last century, Americans’ diets have changed drastically in terms of PUFA
intake. Consumption of LA has increased from 2.79% of energy to 7.21% of energy
while intake of ALA has increased from 0.39% to 0.72%. PUFA consumption has
increased due to the use of vegetable oils in cooking and in processed foods. Changes of
PUFA intake have been related to obesity and metabolic diseases which are associated
with low-grade, chronic inflammation. The overall goal of this project was to study the
effects of dietary PUFA intake on inflammation. To achieve this goal, TWD based PUFA
diets were formulated to represent the 90th and 10th percentiles of intake for both n-6 and
n-3 PUFAs from NHANES report which cover the majority of diets in the United States.
The first hypothesis we had for this project was high n-3 PUFA diet would reduce
acute inflammation caused by LPS, whereas high dietary n-6 PUFA would promote this
process. The results from the first experiment indicate that our PUFA diets had modest
effects on the response to LPS due to the fact that PUFA diets did not have extreme
PUFA contents and ratios. However, some responses under acute inflammation were
observed. HH diet had increased weight gain because of increased fat and lean while the
mice fed with HL diet only had increased fat. That means high n-6 PUFA with low n-3
PUFA in the diet may cause fat accumulation through enhanced lipogenesis. On the other
hand, high dietary n-6 PUFA could promote expression level of lipogenesis and NF-κB
related genes which are positively related to inflammation. Higher overall PUFA content
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could stimulate PPAR-α pathway which is associated to fat oxidation. Except for the
effect on inflammation, dietary PUFA showed a better ability to reduce LDL cholesterol
in the liver than dietary MUFAs.
For the second hypothesis for the thesis, we assumed a chronic inflammation
would be induced by slowly release of LPS in the mice through osmotic mini-pump. Also,
L-Phe supplement in the drinking water would lead to inhibition of IAP activity which
could cause chronic inflammation. The results showed only modest inflammation was
caused by slowly release of LPS. On the other hand, L-Phe supplement did not induce
chronic inflammation.
The third hypothesis we had was long term, low concentration of LPS would
cause chronic inflammation, and a high n-6 PUFA intake would promote the
inflammatory process while high dietary n-3 PUFA would relief the inflammation. From
the results in the experiment, our chronic inflammation model only caused modest
inflammatory responses. However, some differences were observed. For example, high
dietary n-6 level promoted glucose intolerance and reduced insulin sensitivity.
Furthermore, higher n-6 levels in the diet were associated with a significant decrease in
hepatic cholesterol esters.
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